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Foreword	  	  
This	   thesis	   and	   the	   paper	   that	   is	   being	   prepared	   to	   report	   on	   its	   results	   followed	   the	  
Transparent	   Reporting	   of	   Evaluations	   with	   Non-­‐randomized	   Design	   (TREND)	   statement.	  
These	  guidelines	   intend	  to	   improve	  the	  reporting	  of	   theories,	  descriptions	  of	   interventions	  
and	  comparison	  conditions,	   research	  design,	  and	  methods	  of	  adjusting	   for	  possible	  bias	   in	  
evaluation	   studies	   that	   use	   experimental	   nonrandomised	   designs	   (Des	   Jarlais,	   Lyles,	   and	  
Crepaz	  2004).	  	  
These	  guidelines	  were	  chosen	  because	   this	   study	   followed	  a	  quasi-­‐experimental	  design,	  as	  
randomisation	  was	  not	  considered.	  The	  author	  considered	  more	  adequate	  to	  use	  the	  TREND	  
Guidelines	  for	  reporting	  the	  results	  instead	  of	  other	  well	  known	  reporting	  guidelines	  such	  as	  
the	  CONSORT	  List.	  The	  utilisation	  of	  these	  guidelines	  to	  report	  non-­‐randomised	  studies	  has	  
recently	   been	   demonstrated	   to	   have	   a	   greater	   reporting	   completeness	   than	   other	   similar	  
designed	  studies	  that	  don´t	  use	  them	  (even	  when	  controlling	  for	  the	  year	  of	  publication	  and	  
the	  journal	  impact	  factor)	  (Fuller	  et	  al.	  2014).	  Is	  has	  also	  been	  shown	  a	  significant	  association	  
between	   the	   study	  quality	   rating	  and	   the	  use	  of	   TREND	  guidelines	   (Fuller	  et	   al.	   2014).	   For	  
further	  detail	  and	  greater	  ease	  in	  understanding	  the	  chosen	  structure,	  please	  see	  the	  TREND	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Abstract	  
Introduction:	  Benzodiazepines	  are	  the	  most	  utilized	  anxiolytic	  and	  hypnotic	  drugs.	  The	  high	  
consumption	   of	   benzodiazepines	   has	   been	   a	   concern	   due	   to	   the	   reported	   side	   effects	   of	  
long-­‐term	   use	   and	   dependence.	   Portugal	   has	   the	   highest	   benzodiazepine	   utilisation	   in	  
Europe.	  This	  study	  aims	  to	  analyse	  the	  change	  in	  General	  Practitioners’	  (GPs)	  benzodiazepine	  
prescription	  pattern	  after	  an	  intervention	  period.	  	  
Methods:	   An	   educational	   session	   was	   delivered	   to	   a	   group	   of	   intervened	   GPs.	   The	  
benzodiazepine	  prescription	  pattern	  of	  the	   intervened	  group	  was	  compared	  to	  the	  pattern	  
of	   a	   non-­‐intervened	  matched	   group	   from	   the	   same	   region,	   and	   to	   the	   pattern	   of	   another	  
non-­‐intervened	  matched	   group	   from	   a	   different	   region.	   The	   research	   time	   frame	   was	   12	  
month	   before	   and	   after	   intervention.	   The	   analysis	   of	   the	   prescription	   trends	   used	   the	  
Defined	   Daily	   Dose	   (DDD)	   and	   Defined	   Daily	   Dose	   per	   1000	   patients	   per	   day	   (DHD)	  
methodology.	  The	  statistical	  methods	  consisted	  of	  segmented	  regression	  analysis.	  	  
Results:	   There	   was	   a	   decrease	   in	   benzodiazepine	   prescription	   pattern	   of	   intervened	   GPs	  
after	   intervention	   	   (p=0.005).	   There	   was	   also	   a	   decrease	   in	   benzodiazepine	   prescription	  
pattern	   for	   the	   non-­‐intervened	   group	   from	   the	   same	   region	   (p=0.037)	   and	   for	   the	   non-­‐
intervened	   group	   from	   a	   different	   region	   (p=0.010).	   Concerning	   the	   analysis	   by	   gender,	  
female	   gender	   prescribed	   a	   higher	   amount	   of	   benzodiazepines.	   The	   intervened	   female	  
gender	  prescribers	  presented	   the	  highest	  decrease	   in	  prescription	   trend	  after	   intervention	  
(p=0.008).	  
Discussion:	   The	   data	   demonstrated	   that	   the	   intervention	   was	   effective	   in	   reducing	  
benzodiazepine	  prescription	   after	   intervention.	   The	   general	   decrease	   in	   prescription	   trend	  
might	   be	   explained	   by	   a	   Hawthorne	   effect	   or	   a	   contamination	   effect	   between	   the	   three	  
groups	  of	  GPs.	  The	  available	  data	  couldn´t	  explain	  the	  differences	  in	  prescription	  patterns	  by	  
gender.	  	  
Conclusion:	   This	   study	   demonstrates	   how	   a	   single	   intervention	   has	   a	   positive	   impact	   on	  
improving	  prescription	  trends.	  The	  replication	  of	  this	   intervention	  might	  be	  an	  opportunity	  
to	  changing	  the	  worrying	  benzodiazepine	  utilisation	  in	  Portugal.	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Resumo	  	  
Introdução:	  As	  benzodiazepinas	  são	  os	  fármacos	  ansiolíticos	  e	  hipnóticos	  mais	  utilizados.	  O	  
elevado	  consumo	  destes	   fármacos	   tem	  representado	  uma	  preocupação	  devido	  aos	  efeitos	  
secundários	   do	   seu	   uso	   prolongado	   e	   dependência.	   Portugal	   tem	   a	   maior	   utilização	   de	  
benzodiazepinas	   na	   Europa.	   Este	   estudo	   pretende	   analisar	   a	   alteração	   do	   padrão	   de	  
prescrição	  de	  benzodiazepinas	  após	  uma	  intervenção	  com	  clínicos	  gerais.	  	  
Métodos:	  A	   intervenção	   consistiu	  numa	   sessão	  educacional	   a	  um	  grupo	  de	   clínicos	   gerais.	  
Foi	   comparado	   o	   padrão	   de	   prescrição	   de	   benzodiazepinas	   dos	  médicos	   intervencionados	  
com	  o	  de	  um	  grupo	  de	  médicos	  não	  intervencionado	  da	  mesma	  região	  e	  com	  o	  de	  um	  grupo	  
de	  médicos	  não	  intervencionados	  de	  outra	  região.	  Analisaram-­‐se	  as	  prescrições	  de	  12	  meses	  
antes	  e	  depois	  da	  intervenção.	  A	  análise	  do	  padrão	  de	  prescrição	  utilizou	  como	  metodologia	  
a	  Dose	  Diária	  Definida	  (DDD)	  e	  a	  Dose	  Diária	  Definida	  por	  1000	  pacientes	  por	  dia	  (DHD).	  A	  
análise	  estatística	  recorreu	  a	  métodos	  de	  regressão	  segmentada.	  	  	  
Resultados:	  Houve	  uma	  diminuição	  no	  padrão	  de	  prescrição	  de	  benzodiazepinas	  no	  grupo	  
intervencionado	  após	  a	  intervenção	  (p	  =	  0.005).	  Houve	  também	  uma	  redução	  no	  padrão	  de	  
prescrição	   no	   grupo	   não	   intervencionada	   da	   mesma	   região	   (p	   =	   0.037)	   e	   no	   grupo	   não-­‐
intervencionado	   da	   região	   diferente	   (p	   =	   0.010).	   	   Analisando	   por	   género,	   prescritores	   do	  
género	  feminino	  prescrevem	  uma	  quantidade	  maior	  de	  benzodiazepinas.	  Os	  clínicos	  gerais	  
do	   género	   feminino	   intervencionados	   tiveram	   a	   maior	   redução	   na	   prescrição	   após	   a	  
intervenção	  (p	  =	  0.008).	  
Discussão:	   Os	   dados	   demonstraram	   que	   a	   intervenção	   reduziu	   a	   prescrição	   de	  
benzodiazepinas	  após	  a	  intervenção.	  A	  diminuição	  geral	  do	  padrão	  de	  prescrição	  poderá	  ser	  
explicada	  pelo	  efeito	  de	  Hawthorne	  ou	  pela	  contaminação	  entre	  os	   três	  grupos	  de	  clínicos	  
gerais.	   Os	   dados	   disponíveis	   não	   explicam	   as	   diferenças	   nos	   padrões	   de	   prescrição	   por	  
género.	  
Conclusão:	  Este	  estudo	  demonstra	  como	  uma	  única	  intervenção	  tem	  um	  impacto	  positivo	  na	  
melhoria	  dos	  padrões	  de	  prescrição.	  A	  replicação	  desta	  intervenção	  poderá	  representar	  uma	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1.	  Introduction	  
Benzodiazepines	  (herein	  after	  referred	  as	  BZDs)	  are	  the	  most	  utilized	  anxiolytic	  and	  hypnotic	  
drugs.	   The	   first	   benzodiazepine,	   chlordiazepoxide,	  was	   synthesized	   and	   then	   approved	   for	  
use	  in	  1960.	  Until	  then,	  barbiturates	  were	  used	  as	  hypnotics,	  anxiolytics	  and	  sedatives	  with	  a	  
much	   unsafe	   profile	   and	   greater	   lethality	   in	   overdose,	   therefore	   the	   discovery	   of	  
benzodiazepines,	   with	   a	   higher	   safety	   and	   less	   side	   effects	   was	   considered	   very	   positive	  
(Lader	   2011).	   The	   release	   of	   diazepam	   in	   1963	   increased	   benzodiazepines	   popularity	   and	  
soon	   they	   become	   one	   of	   the	   most	   widely	   prescribed	   drugs	   (López-­‐Muñoz,	   Álamo,	   and	  
García-­‐García	   2011).	   	   Until	   then,	   barbiturates	   were	   used	   as	   hypnotics,	   anxiolytics	   and	  
sedatives	   that	   were	   very	   unsafe	   and	   often	   lethal	   in	   overdose	   (2)	   benzodiazepines	   have	   a	  
higher	  margin	  of	  safety	  and	  less	  side	  effects.	  
Benzodiazepines	  are	  positive	  allosteric	  modulators	  for	  GABA-­‐A	  receptors	  in	  sites	  such	  as	  the	  
ventral	  tegmental	  area	  where	  they	  are	  implied	  in	  reward	  circuits	  (Tan,	  Rudolph,	  and	  Lüscher	  
2011).	  	  
Differences	  in	  the	  pharmacological	  profile	  of	  different	  BZDs	  are	  minor.	  Clonazepam	  appears	  
to	  have	  more	  anticonvulsant	  action	   in	   relation	  to	  other	  effects.	  Different	  GABA-­‐A	  receptor	  
isoforms	  are	  believed	  to	  mediate	  sedative	  and	  anxiolytic	  effects.	  They	  are	  active	  orally	  and	  
differ	  mainly	   in	   respect	   to	   their	  duration	  of	  action	   (Rang	  2005).	  Short	  acting	  half-­‐lives	   (like	  
oxazepam	  and	  midazolam)	  are	  metabolised	  to	   inactive	  compounds	  and	  are	  used	  mainly	  as	  
sleeping	  pills.	  Some	  long-­‐acting	  agents	  (like	  diazepam)	  are	  converted	  to	  an	  active	  metabolite	  
(nordazepam)	  (Rang	  2005).	  	  
The	   main	   effects	   of	   benzodiazepines	   are	   reduction	   of	   anxiety,	   sedation	   and	   induction	   of	  
sleep,	   reduction	   of	   muscle	   tone,	   anticonvulsant	   effect	   and	   anterograde	   amnesia	   (Rang	  
2005).	  	  	  
Unwanted	   effects	   of	   these	   drugs	   can	   be	   divided	   into	   toxic	   effects	   resulting	   from	   acute	  
overdosage;	   unwanted	   effects	   occurring	   during	   routine	   therapeutic	   use;	   tolerance	   and	  
dependence	  (Rang	  2005,	  Stevens	  and	  Pollack	  2005).	  	  
The	   high	   consumption	   of	   benzodiazepines	   has	   been	   the	   target	   of	   recent	   studies	   that	  
underscore	   the	  burden	  and	  consequences	  of	   their	   routine	   therapeutic	  use	   that	  often,	  and	  
easily,	  become	  chronic	  and	  excessive	  (Lader	  2011).	  Among	  the	  side	  effects	  associated	  with	  
their	  use	  are	  included	  daytime	  drowsiness,	  slowness	  of	  movements	  and	  thought,	  dizziness,	  
cognitive	   impairment,	   incoordination	   and	   dependence	   (Holbrook	   et	   al.	   2000).	  
Benzodiazepines	   abusive	   utilization	   has	   been	   recently	   related	   to	   dementia	   (de	  Gage	   et	   al.	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2012),	  memory	  problems	  (Stewart	  2005),	  increased	  number	  of	  bone	  fractures	  (Khong	  et	  al.	  
2012),	  a	  highest	  number	  of	  road	  accidents	  (Thomas	  1998),	  and	  possible	  role	  in	  inducing	  the	  
phenomenon	  of	  suicide	  (Carlsten	  et	  al.	  2003,	  Neutel	  and	  Patten	  1997).	  
According	   to	  official	  national	   literature	  and	  OECD	  database,	  BZD	  use	   in	  Portugal	   increased	  
from	   35	   DHD	   since	   the	   late	   eighties	   to	   over	   90	   DHD	   in	   2012	   (Carmona	   and	   Bicho	   2001,	  
António	  et	  al.	  2002,	  Furtado	  and	  Teixeira	  2005,	  2006,	  Furtado,	  Ribeirinho,	  and	  Gaspar	  2010,	  
Furtado	  2013).	  Anxiolytics,	  hypnotics	  and	  sedatives,	  of	  which	  the	  more	  used	  and	  prescribed	  
drugs	  are	  BZDs,	  had	  a	  6%	  increase	  since	  the	  year	  of	  2000.	  This	  high	  utilisation	  was	  signalled	  
and	  considered	  of	  concern	  in	  2006	  by	  the	  International	  Narcotics	  Control	  Board	  (Furtado	  and	  
Teixeira	  2006).	  
A	   general	   comparison	   with	   14	   European	   countries	   shows	   that	   Portugal	   has	   the	   highest	  
utilisation	   of	   BZDs	   in	   Europe	   (Matias	   et	   al.	   2015).	   Even	   in	   a	   more	   detailed	   analysis,	  
considering	   only	   countries	   with	   similar	   12-­‐month	   prevalence	   for	   mental	   disorders,	   with	  
parallel	   results	   for	   negative	   mental	   health	   in	   the	   SF-­‐36	   questionnaire	   (Kovess	   2004),	   and	  
with	   similar	   standardised	  death	   rates	   for	   suicide	   (Gusmão	  et	  al.	   2013),	  Portugal	   is	   still	   the	  
country	  with	  the	  highest	  BZD	  utilisation	  (Matias	  et	  al.	  2015).	  	  
As	   previously	   introduced,	   the	   problem	   of	   benzodiazepine	   over-­‐prescription	   has	   long	   been	  
recognized	  (Furtado	  and	  Teixeira	  2006).	  	  
In	  this	  sense,	  many	   interventions	  have	  been	  tried	   in	  order	  to	  encourage	  doctors	  to	  reduce	  
the	   amount	   of	   benzodiazepines	   they	   prescribe,	   avoiding	   long-­‐term	   prescription	   to	   naïve	  
patients,	   reducing	   and	   discontinuing	   prescription	   to	   patients	   already	   with	   a	   dependence	  
problem	  (Mugunthan,	  McGuire,	  and	  Glasziou	  2011).	  	  
A	  2008	  Cochrane	  review	  demonstrated	  that	  educational	  outreach	  visits	  can	  be	  effective	   in	  
improving	  practice,	  namely	  that	  personal	  visits	  by	  a	  trained	  person	  to	  health	  professional	  are	  
effective	   in	   changing	   prescription	   patterns	   (O’Brien	   et	   al.	   2008).	  More	   specifically,	   a	   2010	  
non-­‐systematic	   review	   showed	   that	   educational	   interventions	   targeted	   at	   General	  
Practitioners	   (GPs)	   had	   significantly	   decreased	   benzodiazepine	   use	   (Smith	   and	   Tett	   2010).	  
The	   same	   study	   indicated	   that	   education	   aiming	   long	   term	   care	   staff	   about	   alternative	  
methods	   to	   treat	   insomnia	   and	   anxiety,	   and	   cutting	   back	   on	   the	   use	   of	   benzodiazepines	  
would	  enhance	  the	  success	  of	  intervention	  (Smith	  and	  Tett	  2010).	  	   	  
The	  Optimizing	  Suicide	  Prevention	  Programmes	  and	  their	   Implementation	   in	  Europe	  (OSPI-­‐
Europe)	   was	   an	   EU	   financed	   intervention	   for	   suicide	   prevention	   focussed	   on	   improving	  
awareness	   and	   care	   for	   depression	   implemented	   in	   four	   countries:	   Ireland,	   Germany,	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Hungary	  and	  Portugal	  (Hegerl	  et	  al.	  2009).	  In	  Portugal,	  the	  project	  was	  implemented	  by	  the	  
department	  of	  Mental	  Health	  in	  NOVA	  Medical	  School	  and	  consisted	  in	  the	  implementation	  
of	  the	  4-­‐level	  model,	  following	  best	  evidence	  guidelines	  (Van	  Der	  Feltz-­‐Cornelis	  et	  al.	  2011):	  
(1)	  training	  sessions	  and	  practice	  support	  aiming	  primary	  health	  care	  professionals,	  (2)	  public	  
relations	  activities	  and	  media	  campaigns,	  (3)	  training	  sessions	  aiming	  community	  facilitators	  
and	  (4)	  outreach	  and	  support	  aiming	  high-­‐risk	  individuals	  through	  self-­‐help	  groups	  (Hegerl	  et	  
al.	  2009,	  Hegerl	  et	  al.	  2008).	  	  
The	   interventions	   in	   the	  OSPI	   Europe	  project	  were	   implemented	   in	   a	   standardized	  way	   to	  
ensure	   comparability	   across	   the	   regions.	   The	   intervention	   was	   evaluated	   according	   to	   a	  
prospective	   and	   controlled	   design.	   Therefore,	   for	   each	   intervened	   region,	   a	   comparable	  
control	   region	   was	   chosen.	   The	   primary	   outcome	   for	   evaluating	   the	   effect	   of	   the	  
intervention	  was	  the	  rate	  of	  suicidal	  acts	  in	  the	  intervention	  and	  control	  regions,	  during	  the	  
18	  months	  of	   intervention	  and	   the	   six	  months	  after.	  As	   intermediate	  outcomes,	   the	   study	  
aimed	   at	   measuring	   the	   effectiveness	   of	   each	   of	   the	   single	   interventions,	   namely	   public	  
attitudes	   and	   knowledge	   towards	   depression	   and	   suicidality,	   effects	   of	   training	   for	  
community	   facilitators	   and	   GPs	   through	   questionnaires,	   quantitative	   and	   qualitative	  
evaluation	   of	   media	   reporting	   on	   suicide	   and	   evaluation	   on	   the	   quality	   of	   the	   treatment	  
provided	   for	   depression	   through	   monitoring	   of	   antidepressants	   and	   other	   psychotropic	  
prescription	  (Hegerl	  et	  al.	  2009).	  	  	  
In	  Portugal,	  the	  region	  of	  Amadora	  was	  chosen	  as	  the	  intervention	  group	  and	  the	  region	  of	  
Almada	   as	   the	   control	   group.	   These	   regions	   were	   chosen	   because	   they	   have	   similar	  
suburban	  context	  (the	  NUTS	  II1	  region	  of	  Lisbon)	  and	  are	  very	  similar	   in	  socio-­‐demographic	  
structure	   and	   population	   pyramids	   for	   both	   genders,	   and	   also	   because	   the	   Tagus	   River	  
separates	   them,	   reducing	   the	   possibility	   of	   contamination.	   Moreover,	   both	   have	   a	  
comparable	   socio-­‐economic	   development	   and	   ethnic	  minorities	  with	   a	   similar	   distribution	  
(Gusmão	  2013).	  According	  to	  the	  investigators	  involved	  in	  the	  OSPI-­‐Europe	  project,	  Amadora	  
was	   selected	   as	   the	   intervention	   area	   because	   there	   was	   already	   a	   consistent	   work	  
performed	   over	   the	   years	   in	   the	   area	   of	   specialized	   mental	   health	   care,	   community	  
intervention	  and	  articulation	  with	  primary	  health	  care	  professionals.	  Thus,	  if	  positive	  results	  
would	  appear,	   they	  could	  be	  derived	  from	  the	  add-­‐ons	  of	  the	  4-­‐level	   implementation	  on	  a	  
well-­‐fit	  set	  of	  resources	  already	  in	  place	  (Gusmão	  2013).	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1	  This	  nomenclature	  was	  originally	  designed	  by	  the	  Eurostat	  to	  define	  units	  of	  territory	  statistical	  analysis.	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Considering	  specifically	  the	  training	  session	  delivered	  to	  Primary	  Health	  Care	  Doctors	  (PHC-­‐
D)	  or	  General	  Practitioners	  (GPs)2,	  the	  focus	  was	  to	  improve	  their	  capacity	  to	  recognise	  signs	  
and	   symptoms	   of	   depression	   and	   suicidal	   ideation	   and	   to	   adequately	   choose	   an	  
antidepressant	   treatment	   simultaneously	   avoiding	   the	   utilization	   of	   benzodiazepines	  
exceeding	   the	   national	   guidelines,	   or	   stimulating	   BZD	   weaning	   in	   patients	   routinely	   using	  
them	  for	  long	  periods.	  In	  this	  context,	  exemplary	  clinical	  cases	  were	  presented,	  such	  as	  the	  
patient	  with	  marked	   depression	   and	   anxiety	   symptoms,	   the	   patient	  with	   insomnia,	   or	   the	  
patient	   with	   abuse	   and/or	   dependency.	   Suggestions	   for	   anxiety	   and	   depressive	   disorders	  
treatment	   were	   also	   included.	   In	   addition,	   the	   approach	   to	   the	   patient	   abusing	  
benzodiazepines	   was	   considered,	   with	   suggestions	   of	   ways	   for	   reducing	   and	   stopping	  
abusive	   utilisation:	   dose	   reduction	   through	   a	   slow	   step-­‐down	   process,	   beginning	   of	  
antidepressant	  therapy	  and	  avoidance	  of	  purchase	  without	  a	  prescription.	  This	  study	  focuses	  
the	  previous	  described	   intervention.	  The	  training	  was	  8-­‐hours	   long,	  credited	  and	   led	  by	  an	  
expert	  and	  senior	  psychiatrist	  consultant.	  
A	  similar	  intervention	  to	  the	  one	  performed	  in	  this	  study	  was	  developed	  in	  Australia	  in	  1999	  
(Dollman	  et	  al.	  2005),	   showing	   that	  a	  multi-­‐strategic	   intervention	   in	  a	   regional	   setting	  was	  
associated	  with	  a	  19%	  reduction	  in	  dispensing	  of	  benzodiazepines	  over	  the	  three	  years	  from	  
the	  pre-­‐project	  to	  follow-­‐up	  period.	  
The	   choice	   for	   defining	   the	   study	   outcomes	   was	   enriched	   by	   the	   know-­‐how	   from	   other	  
studies	   developed	   at	   NOVA	   Medical	   School.	   These	   studies	   focused	   the	   effectiveness	   of	  
educational	  outreach	  visits	  to	  improve	  family	  physician	  prescribing	  by	  analysing	  the	  change	  
in	  prescription	  trend	  of	  anti-­‐inflammatory	  drugs,	  using	  a	  similar	  dataset	  to	  the	  one	  selected	  
to	  the	  present	  study	  (Pinto,	  Caetano,	  Heleno,	  Faria-­‐Vaz,	  et	  al.	  2012,	  Pinto,	  Caetano,	  Heleno,	  
Rodrigues,	  et	  al.	  2012,	  Pinto	  et	  al.	  2014).	  	  
As	  explained	  in	  the	  following	  sections,	  it	  is	  hypothesised	  that	  this	  specific	  training	  to	  general	  
practitioners	   changed	   their	   benzodiazepine	   prescription	   pattern.	   Therefore,	   the	   quality	   of	  
benzodiazepine	   prescription	  would	   improve	  with	   a	   significant	   reduction	   of	   prescription	   in	  




	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
2	  The	  terms	  Primary	  Health	  Care	  Doctors	  (PHC-­‐D)	  and	  General	  Practitioners	  (GPS)	  will	  be	  used	  as	  synonyms	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2.	  Methods	  
This	  study	  follows	  a	  longitudinal	  analysis	  with	  a	  quasi-­‐experimental	  design.	  
2.1.	  Participants	  
The	   OSPI-­‐Europe	   project	   included	   training	   sessions	   to	   GPs.	   This	   intervention	   aimed	   at	  
improving	  their	  ability	  to	  recognise	  and	  treat	  adequately	  depressive	  and	  anxiety	  disorders	  as	  
well	  as	  identifying	  suicidal	  ideation.	  
The	  doctors	   included	   in	   the	   intervention	  group	  were	  contacted,	  by	  email,	  by	   their	  primary	  
health	  care	  unit	  coordinator	  and	  were	  instructed	  to	  attend	  a	  single	  training	  session.	  Both	  the	  
primary	  health	  care	  unit	  coordinator	  and	  the	  GPs	  were	  informed	  about	  the	  duration	  of	  the	  
session,	   the	   trainer	   skills	   and	   it’s	   content	   (practical	   clinical	   training	   on	   how	   to	   better	  
recognise	   signs	   and	   symptoms	   of	   depression	   and	   to	   better	   treat	   anxiety	   and	   depressive	  
disorders).	  There	  were	  quotas	  for	  professionals	  to	  fill	   in	  the	  trainings	  that	  were	  negotiated	  
with	  the	  coordinators:	  at	   least	  50%	  of	  those	  fully	  active.	  The	  rationale	  was	  consensual	  and	  
based	  on	  the	  need	  to	  improve	  primary	  health	  care	  in	  the	  units	  which	  was	  deemed	  to	  be	  an	  
ethical	  issue.	  	  
The	   GPs	   organised	   among	   themselves	   to	   participate	   and	   comply	   with	   the	   quotas.	   No	  
incentive	   or	   reward	   was	   given	   but	   there	   was	   a	   professional	   obligation	   to	   be	   present	  
complying	  with	  the	  quotas	  secondary	  to	  the	  ethical	  imperative.	  The	  doctors	  were	  allowed	  by	  
their	   unit	   coordinator	   to	   attend	   the	   session	   during	   their	   clinical	   work	   schedule.	   All	   the	  
doctors	   willing	   to	   attend	   the	   session	   were	   accepted	   for	   training.	   Randomisation	   was	   not	  
performed,	  neither	  of	  the	  GPs	  included	  nor	  of	  the	  primary	  care	  units	  from	  where	  they	  came	  
from.	  	  
Seventy-­‐one	  doctors	  volunteered	  for	  attending	  the	  training	  and	  authorized	  the	  evaluation	  of	  
the	  knowledge	  acquired	  through	  the	  training	  session.	  They	  also	  authorised	  the	  monitoring	  of	  
their	  prescription	  and	  were	  specifically	  informed	  about	  the	  intention	  to	  evaluate	  the	  change	  
in	  their	  BZD	  prescription	  pattern	  after	  the	  training	  though	  anonymity	  was	  assured.	  	  
This	  study	  includes	  two	  non-­‐intervened	  groups	  of	  GPs:	  one	  coming	  from	  Amadora	  (the	  same	  
region	  as	  the	  intervention	  group)	  and	  another	  coming	  from	  Almada.	  	  
The	   goal	   of	   having	   a	   non-­‐intervened	   group	   of	   GPs	   coming	   from	   the	   same	   region	   as	   the	  
intervention	  group	  was	  to	  identify	  the	  effect	  of	  the	  OSPI-­‐Europe	  project	  on	  the	  prescription	  
pattern	  of	  doctors	  from	  the	  same	  location	  which,	  although	  not	  subjected	  to	  training,	  might	  
have	  been	  influenced	  by	  their	  intervened	  colleagues	  comments	  and	  also	  by	  public	  relations	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activities	   and	   mass	   media	   campaigns	   held	   in	   Amadora.	   This	   group	   included	   148	   doctors	  
prescribing	   in	  Amadora	  (in	  the	  period	  from	  January	  2009	  to	  December	  2013).	   Its	  has	  to	  be	  
highlighted	  that	  these	  numbers	  corresponds	  to	  the	  total	  number	  of	  doctors,	  included	  in	  the	  
ARS	  LVT	  database,	  that	  prescribed	  at	  least	  for	  a	  one	  month	  period	  during	  the	  time	  this	  study	  
was	  developed.	  	  
In	   fact,	   Amadora’s	   primary	   health	   care	   centres	   lost	   almost	   50%	   of	   the	   GPs	   from	   the	  
preparation	   period	   of	   the	   OSPI-­‐Europe	   in	   September	   2008	   until	   the	   beginning	   of	   the	  
trainings	  in	  may	  2010,	  hence	  the	  much	  smaller	  number	  of	  doctors	  included	  in	  training	  (as	  it	  
is	  further	  detailed).	  Actually,	  in	  May	  2010	  there	  were	  90	  GPs	  in	  Amadora	  of	  which	  71	  were	  
trained.	  
The	  non-­‐intervened	  group	  of	  GPs	  coming	  from	  Almada,	  due	  its	  geographical	  location	  (other	  
side	  of	  Tagus	  river)	  was	  expected	  not	  to	  be	  influenced	  during	  the	  time	  that	  the	  OSPI-­‐Europe	  
project	  was	  developed	  in	  Amadora.	  This	  group	  originally	  included	  303	  doctors	  prescribing	  in	  
Almada.	  
For	  each	  control	  group,	  the	  director	  of	  the	  clinical	  council	  for	  the	  primary	  health	  care	  units	  
was	   asked	   the	   permission	   to	   access	   the	   overall	   benzodiazepine	   prescription	   of	   all	   doctors	  
working	  in	  them.	  
	  
Doctors’	  distribution	  
Amadora	   Almada	  
Intervened	   Non-­‐intervened	   Non-­‐intervened	  
71	   148	   303	  
Table	   1.	   Distribution	   of	   General	   Practitioners	   by	   intervention	   and	   non-­‐intervention	   groups,	   considering	   the	   total	   of	   doctors	  
included	  in	  the	  original	  ARS	  ALT	  database.	  
	  
2.2.	  Intervention	  
Under	  the	  OSPI-­‐Europe	  project,	  one	  training	  session	  was	  delivered	  to	   intervened	  GPs.	   	  The	  
OSPI-­‐Europe	   research	   project	   was	   executed	   with	   the	   principles	   laid	   down	   in	   the	   Helsinki	  
declaration	  (2000).	  In	  Portugal,	  the	  Ethical	  Committee	  of	  NOVA	  Medical	  School	  approved	  the	  
research	  protocol	  (ref.	  CE/DP/7-­‐2009)	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The	   intervention	   consisted	   of	   one	   eight-­‐hour	   training	   session.	   The	   content	   focused	   on	  
detecting	  signs	  of	  depression	  and	  anxiety,	  on	  how	  to	  diagnose	  depressive	  disorders	  and	  on	  
how	   to	   specifically	   search	   any	   signs	   of	   suicidal	   ideation.	   Another	   topic	   emphasised	   during	  
the	   training	   session	   was	   the	   need	   for	   adequate	   treatment	   and	   which	   drugs	   should	   be	  
prescribed.	  Role	  modelling	  was	  used	  as	  well	  as	  guidelines.	  
Specifically	   concerning	   adequate	   prescription	   choices,	   the	   focus	   was	   the	   conscientious	  
prescription	   of	   benzodiazepines	   and	   antidepressants.	   In	   the	   case	   of	   antidepressants,	   their	  
clinical	   goal,	   their	  major	   effects	   and	  pharmacological	   actions	   as	  well	   as	   the	   rate	  of	   clinical	  
response,	   good-­‐practice	   monitoring,	   treatment	   phases,	   prototypical	   comorbid	   clinical	  
pictures,	  were	  all	   explored.	  According	   to	  Portuguese	  and	   international	   literature,	   selective	  
serotonin	   reuptake	   inhibitors	   (SSRIs)	   should	   be	   used	   as	   the	   first	   choice	   treatment	   (Simon	  
2002,	  MacGillivray	  et	  al.	  2003,	  Pestana	  and	  Figueira	  2012).	  	  
Moreover,	   some	   details	   of	   other	   antidepressant	   subclasses	   were	   discussed	   and	   it	   was	  
explained	  when	   it	  was	  adequate	   to	   consider	   their	  utilisation.	  Concerning	  benzodiazepines,	  
firstly,	   their	   utilisation	   was	   reviewed	   in	   patients	   suffering	   from	   insomnia	   and	   anxiety.	  
Secondly,	  the	  different	  utilisations	  were	  exposed	  and	  the	  need	  for	   limiting	  the	  prescription	  
to	  a	   treatment	  of	   less	   than	  8	   to	  12	  weeks	   long	  was	  highlighted,	  according	   to	   international	  
guidelines	   and	   national	   recommendations	   (Pestana	   and	   Teixeira	   2011).	   Additionally,	   the	  
approach	  to	  the	  patient	  abusing	  benzodiazepines	  was	  considered,	  with	  suggestions	  of	  ways	  
for	   reducing	  and	  stopping	  abusive	  utilisation:	  dose	   reduction,	   switching	   for	  antidepressant	  
treatment,	  and	  avoidance	  of	  purchase	  without	  a	  prescription.	  
The	  intervention	  was	  repeated	  to	  seven	  groups	  of	  GPs	  in	  five	  different	  months	  (May	  2010,	  
June	  2010,	  October	  2010,	  November	  2010	  and	  March	  2011)	  and	  was	  delivered	  always	  by	  the	  
same	   team,	  which	  was	   composed	   by	   a	   psychiatrist	   and	   a	   psychologist	   as	   co-­‐trainer.	   They	  
always	  presented	  the	  same	  slides,	  performed	  the	  same	  role-­‐modelling	  sessions,	  distributed	  
the	  same	  videos	  and	  made	  an	  effort	  to	  replicate	  the	  training	  in	  a	  similar	  way.	  	  
The	  training	  was	  set	  in	  a	  conference	  room	  specifically	  prepared	  for	  that	  event.	  	  
Each	  participant	  was	  exposed	  to	  a	  single	   intervention.	  This	  was	  the	  only	  session	  delivered,	  
and	  besides	   the	  moment	  of	  evaluation	  of	   the	  acquired	  knowledge,	  no	   further	  contact	  was	  
established	  between	   the	   investigation	   team	  and	   the	   intervened	  GPs,	  but	  desktop	  placards	  
with	  memos	  and	  core	  information	  were	  distributed.	  
All	   GPs	   included	   in	   the	   OSPI-­‐Europe	   project	   gave	   their	   informed	   consent.	   This	   document	  
included	   authorization	   to	   analyse	   the	   BZDs	   and	   antidepressant	   prescriptions	   of	   the	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intervened	  doctors,	  and	   to	  evaluate	   the	  effectiveness	  of	   training	   in	   the	  acquisition	  of	  new	  
knowledge	   and	   changing	   attitudes.	   Concerning	   the	   non-­‐intervened	   groups	   of	   GPs,	   an	  
authorisation	   was	   obtained	   from	   the	   primary	   health	   care	   centres’	   executive	   president	   in	  
order	  to	  analyse	  the	  same	  content	  coming	  from	  their	  prescriptions.	  	  
2.3.	  Objectives	  
The	   primary	   objective	   of	   this	   study	   was	   to	   evaluate	   the	   change	   in	   benzodiazepine	  
prescription	  pattern	  after	  a	  training	  session	  delivered	  to	  GPs.	  The	  secondary	  objective	  was	  to	  
compare	   the	   prescription	   trend	   in	   the	   intervened	   group	   of	   doctors	  with	   the	   trend	   of	   two	  
other	  groups	  of	  non-­‐intervened	  doctors	  prescribing	  in	  the	  same	  type	  of	  primary	  health	  care	  
centres,	  globally	  and	  by	  gender.	  
	  2.4.	  Outcomes	  
The	   primary	   outcome	   for	   this	   investigation	   was	   the	   change	   in	   the	   prescription	   pattern	  
(globally	   and	   by	   gender)	   of	   intervened	   GPs	   who	   were	   given	   training	   about	   correct	  
benzodiazepine	  prescription.	  	  
A	   secondary	   outcome	   for	   this	   study	   was	   the	   change	   in	   the	   prescription	   trend	   of	   non-­‐
intervened	   GPs	   coming	   from	   the	   same	   region	   as	   the	   intervened	   group	   and	   of	   the	   non-­‐
intervened	  GPs	  coming	  from	  a	  different	  region.	  	  
For	  the	  analysis	  of	  the	  trends	  in	  the	  prescription	  the	  Defined	  Daily	  Dose	  (DDD)	  methodology	  
proposed	  by	   the	  World	  Health	  Organization	   (WHO)	  was	  used,	  which	  allows	  aggregation	  of	  
data	   across	   drug	   groups	   and	   comparisons	   between	   countries,	   regions	   and	   health	   facilities	  
(WHO	  2003).	  	  
The	  Defined	  Daily	  Doses	  (DDD)	  for	  the	  monthly-­‐prescribed	  benzodiazepines	  was	  computed	  
as	  follows:	  	  
DDD =∑ (# items.per.package)*(amount.of .drug.per.item(mg))*(# packages)Defined.Daily.Dose( for.each.drug) 	  
Equation	  1.	  Formula	  used	  to	  compute	  benzodiazepine	  DDD	  
This	   methodology	   was	   preferred	   to	   the	   more	   straightforward	   analysis	   of	   the	   number	   of	  
prescriptions	   or	   the	   number	   of	   packages	   prescribed	   because	   each	   prescription	   could	  
correspond	   to	   a	   very	   different	   quantity	   of	   drug.	   To	   exemplify,	   the	   difference	   between	  
prescribing	  a	  package	  of	  0.5mg	  dosage	  of	  alprazolam	  with	  30	  pills	  (15	  DDDs)	  and	  a	  package	  
of	   1mg	   dosage	   of	   the	   same	   substance	   with	   60	   pills	   (60	   DDDs),	   could	   only	   be	   taken	   into	  
account	  using	  the	  chosen	  methodology.	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Then,	  for	  comparison	  and	  trend	  analysis,	  the	  Defined	  Daily	  Doses	  per	  1000	  patients	  per	  day	  




Equation	  2.	  Formula	  used	  to	  compute	  benzodiazepine	  DHD	  
It	   has	   to	   be	   highlighted	   that	   the	   previous	   equation	   usually	   uses	   the	   overall	   number	   of	  
inhabitants	  to	  whom	  the	  drug	  might	  be	  offered	  in	  the	  specific	  period	  of	  time.	  However,	  the	  
total	   number	   of	   patients	   observed	   by	   month	   by	   each	   doctor	   was	   chosen	   instead,	   as	   a	  
significant	  proportion	  of	   the	  population	   in	  2009-­‐2012	   still	   hadn´t	  an	  assigned	  GP.	  The	  ARS	  
LVT	   also	   provided	   this	   data.	   In	   some	   cases,	   the	   data	   provided	   for	   the	   number	   of	   patients	  
observed	   was	   missing	   or	   the	   number	   provided	   was	   substantially	   low	   compared	   to	   the	  
number	  of	  prescriptions	  included	  in	  the	  original	  prescription	  database.	  In	  those	  cases,	  it	  was	  
chosen	  to	  replace	  the	  number	  of	  patients	  observed	  by	  the	  number	  of	  patients	  to	  whom	  any	  
prescription	  had	  been	  included	  in	  the	  original	  database.	  	  
In	  order	  to	  perform	  the	  statistical	  analysis	  concerning	  the	  comparison	  of	  prescription	  trends	  
between	   the	   three	   groups	   of	  GPs	   (intervened	  GPs	   coming	   from	  Amadora;	   non-­‐intervened	  
GPs	  coming	  from	  Amadora;	  and	  non-­‐intervened	  GPs	  coming	  from	  Almada)	  the	  Defined	  Daily	  




Equation	  3.	  Formula	  used	  to	  compute	  benzodiazepine	  DHD	  aggregated	  by	  group	  of	  GP	  included	  in	  the	  analysis	  
For	   the	   general	   analysis	   by	   group	   of	  GPs,	   the	  mean	  monthly	  DHD	  was	   found	   through	   the	  
following	  method:	  since	  intervened	  doctors	  were	  not	  trained	  on	  the	  same	  moment	  in	  time	  
(the	   interventions	   happened	   in	   5	   different	  months	   through	   a	   period	   of	   10	  months),	   each	  
group	   of	   doctors	   intervened	   on	   the	   same	   month	   and	   the	   two	   matching	   non-­‐intervened	  
groups	  had	  a	  specific	  time	  scale	  (so	  for	  each	  group	  there	  might	  be	  5	  different	  timescales).	  In	  
order	  to	  have	  a	  single	  time	  scale	  for	  the	  intervened	  group	  in	  Amadora,	  the	  non-­‐intervened	  
group	   in	   Amadora	   and	   the	   non-­‐intervened	   group	   in	   Almada,	   the	   mean	   value	   for	   the	  
prescribed	   DHD	   corresponding	   to	   the	   same	   moment	   in	   the	   time	   scale	   was	   computed	  
(meaning	   that	   for	   the	   same	   timescale	   moment	   a	   single	   DHD	   value	   corresponding	   to	   the	  
mean	  monthly	  prescribed	  DHD	  was	  found	  for	  every	  group	  of	  doctors	  intervened	  in	  the	  same	  
moment).	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For	  the	  analysis	  of	  the	  trend	  in	  benzodiazepine	  prescription	  by	  gender	  for	  each	  group	  of	  GPs	  
the	  mean	  monthly-­‐prescribed	   DHD	   by	   females	   and	   the	  mean	  monthly-­‐prescribed	   DHD	   by	  
males	  were	  calculated	  for	  each	  group	  of	  GPs.	  	  
2.5.	  Sample	  size	  
This	  study	  included	  the	  total	  benzodiazepine	  prescriptions	  coming	  from	  the	  doctors	  selected	  
for	   analysis	   between	   the	   12	  months	   before	   and	   after	   the	   intervention	   period	   (please	   see	  
next	   section	   for	   further	   detail	   on	   the	   assignment	   of	   participants).	   This	   included	   146.284	  
individual	   benzodiazepine	   prescriptions,	   51.342	   from	   the	   intervened	   GP	   group	   from	  
Amadora,	  30.572	  from	  the	  non-­‐intervened	  group	  of	  GPs	  from	  Amadora	  and	  64.370	  from	  the	  
non-­‐intervened	  group	  of	  GPs	  from	  Almada.	  	  
2.6.	  Assignment	  method	  
Of	  the	  original	  71	  trained	  doctors,	  only	  57	  could	  be	  included	  in	  this	  study	  because	  14	  hadn´t	  
their	  prescriptions	  associated	  with	  the	  Regional	  Health	  Administration	  of	  Lisbon	  and	  Tagus	  
Valley	  (Administração	  Regional	  de	  Saúde	  de	  Lisboa	  e	  Vale	  do	  Tejo,	  herein	  after	  referred	  to	  as	  
ARS	  LVT)	  database	   for	  primary	  health	  care	  prescriptions.	  This	  happened	  mostly	  because	   in	  
2009	   the	   ARS	   LVT	   system	   missed	   some	   prescriptions	   (for	   example	   prescriptions	   filled	   by	  
hand	   that	   were	   not	   introduced	   in	   the	   computerised	   database	   system),	   and	   also	   because	  
some	  doctors	  were	  not	  primarily	  prescribing	  at	  a	  primary	  health	  care	  unit	  of	  Amadora	   (so	  
the	  bulk	  of	  their	  prescriptions	  was	  performed	  elsewhere),	  or	  because	  some	  were	  first	  year	  
residents	  (so	  during	  the	  follow-­‐up	  period	  their	  prescriptions	  changed	  to	  another	  location).	  In	  
one	  case,	  although	  the	  doctor	  was	  trained,	  there	  weren´t	  any	  prescriptions	   included	  in	  the	  
ARS	  LVT	  database	  in	  the	  follow-­‐up	  period.	  	  
Of	  the	  total	  57	  GPs	  intervened,	  22	  came	  from	  “Family	  Health	  Units”	  –	  herein	  after	  referred	  
as	  USFs,	  the	  Portuguese	  acronym.	  A	  slightly	  higher	  number	  of	  GPs	  (35)	  came	  from	  “Primary	  
Health	  Care	  Units”	  –	  herein	  after	  referred	  as	  UCSPs,	  the	  Portuguese	  acronym.	  It	  is	  important	  
to	   stress	   that	   these	   two	   types	   of	   primary	   health	   care	   units	   have	   significantly	   different	  
management	   criteria.	   The	  USFs	   are	   based	   in	   a	  more	   regulated	  model	   of	   care,	   and	   doctor	  
practicing	   in	   this	   type	   of	   unit	   receive	   monetary	   incentives	   based	   on	   better	   clinical	  
performance,	   which	   is	   defined	   by	   an	   annually	   signed	   agreement	   between	   the	   Regional	  
Health	   Administration	   and	   the	   USF’s	   regional	   executive	   director.	   The	   UCSPs	   are	   less	  
regulated	  and	  organised.	  	  
The	   doctors	   chosen	   to	   integrate	   the	   two	   control	   groups	   (Amadora	   non-­‐intervened	   and	  
Almada)	  were	  firstly	  selected	  taking	   into	  account	  that	  they	  were	  practicing	  and	  prescribing	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in	   the	   same	   month	   that	   the	   intervention	   was	   held.	   Since	   the	   original	   dataset	   contained	  
benzodiazepines	   prescriptions	   data	   from	   January	   2009	   to	   December	   2013,	   some	   doctors	  
whose	   prescriptions	   ended	   before	   or	   started	   after	   the	   date	   of	   the	   training	   sessions	  were	  
excluded.	  	  
For	   each	   group	  of	   doctors	   that	  were	   trained	   in	   the	   same	  month,	   two	  matching	   groups	   of	  
non-­‐intervened	  doctors	  were	  selected.	  This	  selection	  took	  into	  account	  the	  type	  of	  primary	  
health	  care	  facility	  where	  the	  GPs	  were	  prescribing.	  	  
	  
Doctors’	  distribution	  after	  matching	  







35	  UCSPs	   22	  USFs	   30	  UCSPs	   14	  USFs	   35	  UCSPs	   22	  USFs	  
Table	  2:	  Distribution	  of	  general	  practitioners	  included	  in	  the	  analysis	  after	  matching.	  	  
	  
More	   specifically:	   for	   every	  GP	   trained	   in	   Amadora	   at	   a	   specific	  month,	   it	  was	  matched	   a	  
non-­‐intervened	  GP	  from	  Amadora	  and	  a	  non-­‐intervened	  GP	  from	  Almada	  prescribing	  in	  the	  
same	  type	  of	  primary	  care	  unit,	  either	  USF	  or	  UCSP.	  It	  has	  to	  be	  highlighted	  that	  for	  Almada	  
it	  was	  possible	  to	  obtain	  a	  1-­‐1	  match,	  however	  regarding	  Amadora,	  the	  number	  of	  doctors	  
available	  was	  insufficient	  so	  we	  used	  average	  DHD	  (see	  above	  table).	  
2.7.	  Units	  of	  Analysis	  
A	   database	   provided	   by	   the	   Information	   System	   of	   the	   ARS	   LVT	   was	   used.	   This	   database	  
initially	   included	   all	   benzodiazepines’	   prescriptions	   reimbursed	   by	   the	   National	   Health	  
System	  (NHS)	  beneficiaries	  from	  GPs	  working	  at	  primary	  health	  care	  centres	  in	  Almada	  and	  
Amadora	   from	   January	   2009	   to	   December	   2013.	   It	   did	   not	   considered	   prescriptions	  
reimbursed	  by	  other	  health	  care	  reimbursements	  systems.	  	  
The	   sample	   selected	   for	   this	   study	   derived	   from	   the	   previously	   mentioned	   dataset.	  
Prescriptions	  included	  for	  statistical	  analysis	  came	  from	  the	  158	  GPs	  selected	  after	  matching	  
and	  corresponded	  to	  the	  designated	  time	  frame	  for	  the	  investigation:	  12	  months	  before	  to	  
12	  month	  after	  the	  intervention	  period.	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ARS	   LVT	   provided	   the	   dataset	   after	   the	   study	   protocol	   for	   the	   present	   investigation	   was	  
evaluated	  and	  approved	  by	  the	  ARS	  LVT	  Ethics	  Committee	  for	  Health	  (please	  see	  document	  
in	  attachment).	  
The	   original	   database	   contained	   635.216	   entries.	   Each	   database	   entry	   corresponded	   to	   a	  
prescription	  containing	  BZDs	  to	  an	  individual	  patient.	  	  
The	  benzodiazepines	  included	  in	  this	  study	  are	  detailed	  in	  the	  following	  table:	  	  
List	  of	  benzodiazepines	  included	  in	  data	  analysis	  
Alprazolam	   Estazolam	   Midazolam	  
Bromazepam	   Ethyl	  Loflazepate	   Oxazepam	  
Brotizolam	   Flurazepam	   Potassium	  Clorazepate	  
Chlordiazepoxide	   Halazepam	   Prazepam	  
Clobazam	   Ketazolam	   Temazepam	  
Clonazepam	   Loprazolam	   Triazolam	  
Cloxazolam	   Lorazepam	   Zolpidem	  
Diazepam	   Mexazolam	   	  
Table	  3:	  List	  of	  benzodiazepines	  included	  in	  data	  analysis.	  
For	  each	  entry	   in	  the	  dataset,	  the	  following	  information	  was	  originally	   included:	  the	  region	  
and	   specific	   primary	   health	   care	   unit	   where	   the	   prescription	   was	   performed;	   the	   year,	  
month	  and	  day	  of	  prescription;	  the	  number	  of	  registration	  in	  the	  Portuguese	  Medical	  Board	  
that	   was	   utilised	   to	   identify	   each	   prescriber;	   an	   encrypted	   identification	   code	   for	   every	  
patient;	   patient´s	   age;	   patient’s	   gender;	   the	   benzodiazepine	   generic	   name;	   the	  
benzodiazepine	   brand	   name;	   dosage	   per	   formulation	   (in	   milligrams);	   number	   of	   pills	   (or	  
equivalent	  if	  liquid	  formulation)	  per	  package;	  the	  number	  of	  packages	  prescribed.	  	  
In	   order	   to	   answer	   the	   investigation	   objectives,	   based	   on	   the	   original	   available	   data,	   the	  
following	  information	  was	  added	  to	  every	  entry	  on	  the	  database:	  a	  continuous	  variable	  with	  
the	   calculation	   of	   the	   Defined	   Daily	   Dose	   (DDD)	   corresponding	   to	   each	   prescription	  
(calculation	  performed	  as	  previously	  detailed	  in	  the	  outcomes	  section,	  using	  the	  dosage	  per	  
pill	  or	  equivalent	  formulation	  (in	  milligrams);	  number	  of	  pills	  or	  equivalent	  formulation	  per	  
package	  and	  the	  number	  of	  packages	  which	  was	  available	   in	  the	  original	  dataset);	  a	  binary	  
variable	   (NO/YES)	   identifying	   the	   doctors	   that	   were	   intervened;	   GP’s	   gender;	   number	   of	  
patients	  observed	  by	  each	  doctor	  per	  month	  (additional	   information	  asked	  to	  the	  ARS	  LVT,	  
essential	   to	  compute	   the	   total	  benzodiazepine	  quantity	  prescribed	  by	  month	  as	  previously	  
detailed	  further	  the	  outcomes	  section);	  a	  binary	  variable	  (UCSP/USF)	  allowing	  to	  identify	  the	  
type	   of	   primary	   health	   care	   unit;	   a	  monthly	   time	   scale	   (from	   -­‐12	   to	   12)	   in	  which	   the	   “0”	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moment	   corresponds	   to	   the	   month	   of	   intervention,	   “1”	   corresponds	   to	   one	   month	   after	  
intervention	  and	  “-­‐1”	  corresponds	  to	  one	  month	  before	  intervention	  (and	  so	  on	  for	  the	  total	  
25	  months-­‐time	  included	  in	  this	  investigation).	  
The	   final	   dataset	   used	   to	   perform	   the	   overall	   analysis	   excluded	   the	   following	   data:	  
prescriptions	  coming	  from	  GPs	  that	  were	  not	  prescribing	  by	  the	  time	  the	  interventions	  were	  
delivered;	  prescriptions	  not	   concerning	   the	   study	   timeframe	   (from	   -­‐12	   to	  12	  months	  after	  
training).	  This	  dataset	  comprised	  146.284	  entries.	  	  
2.8.	  Statistical	  Methods	  
For	   the	   general	   analysis	   on	   the	   prescription	   trend	   of	   each	   group	   of	   GPs,	   a	   segmented	  
regression	  analysis	  was	  performed.	  This	  is	  a	  statistical	  method	  suitable	  for	  estimating	  effects	  
in	   interrupted	  time	  series	  studies	   in	  order	  to	  conclude	  about	  the	  impact	  of	  an	  intervention	  
on	  the	  measure	  of	  interest	  (DHD	  in	  this	  study).	  
For	   the	   analysis	   of	   the	   prescription	   trend	   of	   each	   group	   of	   GPs	   by	   gender,	   a	   descriptive	  
graphical	  analysis	  was	  performed	   in	  order	   to	  verify	   the	   influence	  of	  gender	  on	  the	  general	  
prescription	  trend.	  	  	  
The	  statistical	  analyses	  were	  performed	  using	  STATA	  (StataCorp	  2013) and the	  R	  Project	  for	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3.	  Results	  
3.1.	  General	  analysis	  
This	   study	   included	   51.342	   prescriptions	   from	   intervened	   Amadora	   GPs	   group,	   30.572	  
prescriptions	   from	   non-­‐intervened	   Amadora	   GPs	   group	   and	   64.370	   prescriptions	   from	  
Almada	   GPs	   group.	   In	   the	   following	   figure	   a	   decreasing	   trend	   in	   benzodiazepines	  
prescription	   is	   shown	   in	   the	   intervened	   group	   and	   also,	  more	   slightly,	   in	   the	   prescription	  
trend	  of	  non-­‐intervened	  groups	  from	  Amadora	  and	  Almada.	  	  
	  
Figure	  1.	  Graphical	  descriptive	  analysis	  of	  the	  mean	  DHD	  values	  trend	  by	  group	  of	  GPs.	  	  
	  
In	   order	   to	   verify	   the	   change	   in	   the	   prescription	   pattern	   after	   training,	   a	   segmented	  
regression	   analysis	   was	   performed	   and	   the	   following	   graphical	   analysis	   demonstrates	   the	  
slopes	  for	  the	  fitted	  DHD	  values.	  
	  
Figure	  2.	  Graphical	  analysis	  of	  DHD	  mean	  values	  trend	  for	  the	  intervened	  Amadora	  group.	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The	   graphical	   analysis	   for	   the	   benzodiazepines	   prescription	   trend	   in	   the	   intervened	   group	  
shows	  that	  there	  was	  a	  decrease	  in	  the	  trend	  just	  after	  the	  intervention.	  	  
The	  following	  regression	  analysis	  demonstrates	  that	  there	  was	  a	  non-­‐statistically	  significant	  
increasing	  prescription	  trend	  before	  intervention	  (slope	  before	  intervention=3.937;	  p=0.161)	  
and	   a	   significant	   decreasing	   prescription	   trend	   after	   the	   intervention	   (slope	   after	  
intervention=-­‐7.488	  with	  a	  p=0.005).	  
	  
Mean	  DHD	   Coef.	   95%	  conf.	  interval	   Std.	  Err.	   p	  
Intercept	  (before)	  
intervention	  
394.231	   352.739	  -­‐	  435.723	   19.952	   <0.001	  
Intercept	  (after)	  
intervention	  
399.917	   364.581	  -­‐	  435.253	   16.991	   <0.001	  
Slope	  (before)	  
intervention	  
3.937	   -­‐1.700	  -­‐	  9.575	   2.711	   0.161	  
Slope	  (after)	  
intervention	  
-­‐7.488	   -­‐12.485	  -­‐	  2.491	   2.403	   0.005	  
Table	  4.	  Regression	  analysis	  for	  prescriptions	  of	  intervened	  group	  from	  Amadora.	  Intercept	  before	  intervention	  is	  the	  predicted	  
mean	  at	  time	  -­‐1;	  Intercept	  after	  intervention	  is	  the	  predicted	  mean	  at	  time	  0;	  Slope	  before	  intervention	  is	  the	  slope	  when	  the	  
time	  scale	  is	  less	  than	  0;	  Slope	  after	  intervention	  is	  the	  slope	  when	  the	  time	  scale	  is	  0	  or	  higher.	  
	  
Furthermore,	   an	   analysis	   was	   performed	   to	   compare	   the	   slopes	   before	   and	   after	   the	  
intervention	   and	   a	   significant	   difference	   between	   slopes	   was	   found	   (difference	   between	  
slopes	   =	   -­‐11.43	   with	   a	   p=0.005).	   Since	   this	   difference	   is	   negative,	   a	   decrease	   in	  
benzodiazepine	  prescription	  after	  the	  intervention	  was	  demonstrated.	  
In	  order	   to	  verify	   the	  prescription	   trend	   in	   the	  non-­‐intervened	  group	  of	  GPs	  prescribing	   in	  
the	   same	   area	   as	   the	   intervened	   group	   (Amadora),	   the	   same	   analysis	   was	   performed,	   as	  
previously	  described.	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Figure	  3.	  Graphical	  analysis	  of	  DHD	  mean	  values	  trend	  for	  the	  non-­‐intervened	  Amadora	  group.	  
	  
	  
The	   following	   regression	  analysis	  demonstrates	   that	   there	  was	  a	  non-­‐significant	   increasing	  
prescription	  trend	  before	  the	  intervention	  period	  	  (slope	  before	  intervention	  =3.282	  with	  a	  
p=0.193)	  and	  a	  decreasing	  prescription	  trend	  after	  the	  intervention	  (slope	  after	  intervention	  
=-­‐4,020	  with	  a	  p=0.079).	  
Mean	  DHD	   Coef.	   95%	  conf.	  interval	   Std.	  Err.	   p	  
Intercept	  (before)	  
intervention	  
308.478	   270.843	  -­‐	  346.112	   18.097	   <0.001	  
Intercept	  (after)	  
intervention	  
326.104	   294.054	  -­‐	  358.155	   15.412	   <0.001	  
Slope	  (before)	  
intervention	  
3.282	   -­‐1.831	  -­‐	  8.396	   2.459	   0.196	  
Slope	  (after)	  
intervention	  
-­‐4.020	   -­‐8.553	  -­‐	  0.5122	   2.179	   0.079	  
Table	   5.	   Regression	   analysis	   for	   prescriptions	   of	   non-­‐intervened	   group	   from	   Amadora.	   Intercept	   before	   intervention	   is	   the	  
predicted	  mean	  at	  time	  -­‐1;	  Intercept	  after	  intervention	  is	  the	  predicted	  mean	  at	  time	  0;	  Slope	  before	  intervention	  is	  the	  slope	  
when	  the	  time	  scale	  is	  less	  than	  0;	  Slope	  after	  intervention	  is	  the	  slope	  when	  the	  time	  scale	  is	  0	  or	  higher.	  
	  
As	   previously,	   an	   analysis	   was	   performed	   to	   compare	   the	   slopes	   before	   and	   after	   the	  
intervention	   period	   and	   a	   significant	   difference	   between	   slopes	   was	   found	   (difference	  
between	   slopes	   =-­‐7.30	   with	   a	   p=0.037).	   Since	   this	   difference	   is	   negative	   a	   decrease	   in	  
benzodiazepine	  prescription	  after	  the	  intervention	  period	  was	  demonstrated.	  
In	  order	   to	  verify	   the	  prescription	   trend	   in	   the	  non-­‐intervened	  group	  of	  GPs	  prescribing	   in	  
Almada,	  once	  again	  the	  same	  analysis	  was	  performed.	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Figure	  4:	  Graphical	  analysis	  of	  DHD	  mean	  values	  trend	  for	  the	  non-­‐intervened	  Almada	  group.	  
	  
	  
The	   following	   regression	   analysis	   demonstrates	   that	   there	   was	   an	   increasing	   trend	   in	  
benzodiazepine	   prescription	   before	   intervention	   (slope	   before	   intervention	   =2.889	   with	   a	  
p=0.036)	  and	  a	  decreasing	  prescription	  trend	  after	  the	  intervention	  (slope	  after	  intervention	  
=-­‐1.997	  with	  a	  p=0.096).	  
Mean	  DHD	   Coef.	   95%	  conf.	  interval	   Std.	  Err.	   p	  
Intercept	  (before)	  
intervention	  
285.886	   266.093	  -­‐	  305.679	   9.518	   <0.001	  
Intercept	  (after)	  
intervention	  
272.231	   255.375	  -­‐	  289.087	   8.106	   <0.001	  
Slope	  (before)	  
intervention	  
2.889	   0.199	  -­‐	  5.578	   1.293	   0.036	  
Slope	  (after)	  
intervention	  
-­‐1.997	   -­‐4.381	  -­‐	  0.387	   1.146	   0.096	  
Table	   6.	   Regression	   analysis	   for	   prescriptions	   of	   non-­‐intervened	   group	   from	   Almada.	   Intercept	   before	   intervention	   is	   the	  
predicted	  mean	  at	  time	  -­‐1;	  Intercept	  after	  intervention	  is	  the	  predicted	  mean	  at	  time	  0;	  Slope	  before	  intervention	  is	  the	  slope	  
when	  the	  time	  scale	  is	  less	  than	  0;	  Slope	  after	  intervention	  is	  the	  slope	  when	  the	  time	  scale	  is	  0	  or	  higher.	  
An	  analysis	   to	  compare	  the	  slopes	  before	  and	  after	   intervention	  was	  performed	  and	  there	  
was	  a	  significant	  difference	  between	  these	  slopes	  (difference	  between	  slopes	  =-­‐4.886	  with	  a	  
p=0.010).	   Since	   this	   difference	   is	   negative	   a	   decrease	   in	   benzodiazepine	   prescription	   after	  
the	  intervention	  was	  demonstrated.	  
Finally,	   a	   comparison	   between	   the	   slopes	   for	   the	   different	   groups	   of	   GPs	   included	   in	   this	  
study	  was	  performed.	  This	  analysis	  demonstrated	  that	  there	  was	  no	  significant	  difference	  in	  
the	  slopes	  before	  (p=0.859)	  and	  the	  slopes	  after	   intervention	  (p=0.290)	  for	   intervened	  and	  
non-­‐intervened	   groups	   in	   Amadora.	   Also	   there	  was	   no	   significant	   difference	   between	   the	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slopes	  before	  (p=0.889)	  and	  the	  slopes	  after	   intervention	  (p=0.417)	  for	  the	  non-­‐intervened	  
group	  of	  Amadora	  and	  for	  the	  group	  from	  Almada.	  	  
When	   comparing	   the	   slopes	   before	   and	   the	   slopes	   after	   intervention	   for	   the	   intervened	  
group	  in	  Amadora	  and	  the	  non-­‐intervened	  group	  in	  Almada,	  the	  same	  analysis	  demonstrates	  
no	   significant	   different	   in	   the	   slopes	   before	   the	   intervention	   (p=0.728),	   but	   there	   is	   a	  
significant	  difference	  in	  the	  slopes	  after	  intervention	  (p<0.001).	  	  
Finally,	   it	   should	   be	   highlighted	   that	   all	   the	   graphical	   analysis	   showed	   an	   increase	   in	  
benzodiazepine	  prescription	  around	  the	  10th	  month	  after	  the	  intervention	  period.	  
3.2.	  Analysis	  by	  prescribers’	  gender	  	  
A	  more	  in	  depth	  analysis	  was	  performed	  in	  order	  to	  study	  the	  prescription	  pattern	  according	  
to	  prescribers’	  gender.	  	  
Of	   the	   total	   benzodiazepines	   prescribed	   by	   the	   intervened	   group	   from	   Amadora,	   31.249	  
came	   from	  37	   female	  prescribers	  and	  20.093	  came	   from	  20	  male	  prescribers.	  Of	   the	   total	  
benzodiazepines	  prescribed	  by	  the	  non-­‐intervened	  group	  from	  Amadora,	  21.011	  came	  from	  
28	   female	   prescribers	   and	   9.561	   came	   from	   16	   male	   prescribers.	   Of	   the	   total	  
benzodiazepines	   prescribed	   by	   the	   non-­‐intervened	   group	   of	   GPs	   coming	   from	   Almada,	  
36.228	  came	  from	  33	  female	  prescribers	  and	  28.142	  came	  from	  24	  male	  prescribers.	  	  
	  
Figure	  5.	  Spaghetti	  plot	  for	  individual	  benzodiazepine	  prescribing	  profile	  of	  all	  doctors	  involved	  in	  the	  study.	  
Figure	  5	  illustrates	  the	  individual	  prescribing	  profile	  of	  all	  the	  doctors	  involved	  in	  this	  study.	  
This	  analysis	  demonstrates	  that	  female	  prescribers	  have	  higher	  benzodiazepine	  prescription.	  
To	  further	  investigate	  differences	  in	  prescription	  trends	  between	  genders,	  a	  detailed	  analysis	  
was	  performed	  for	  each	  group	  included	  in	  the	  study.	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Figure	  6:	  Spaghetti	  plot	  for	  individual	  benzodiazepine	  prescribing	  profile	  of	  intervened	  GPs	  from	  Amadora.	  	  	  
	  
Figure	  7:	  Spaghetti	  plot	  for	  individual	  benzodiazepine	  prescribing	  profile	  of	  non-­‐intervened	  GPs	  from	  Amadora	  	  
	  
Figure	  8:	  Spaghetti	  plot	  for	  individual	  benzodiazepine	  prescribing	  profile	  of	  non-­‐intervened	  GPs	  from	  Almada	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This	   analysis	   brought	   to	   light	   the	   existence	  of	   a	   difference	  between	  prescription	   trends	   in	  
female	  and	  male	  prescribers.	  In	  order	  to	  explore	  this	  difference,	  an	  analysis	  of	  prescription	  
trend	  by	  gender	  and	  a	  comparison	  of	  the	  slopes	  for	  the	  prescription	  trend	  before	  and	  after	  
the	  intervention	  period	  were	  performed	  for	  each	  group.	  	  	  
	  
Figure	  9:	  Graphical	  analysis	  of	  the	  mean	  DHD	  prescribing	  pattern	  by	  gender	  –	  overall	  trend	  for	  all	  the	  doctors	  included	  in	  the	  
study.	  
The	  previous	  graph	   illustrates	   the	  overall	  mean	  prescribing	   trend	  of	  benzodiazepines	  of	  all	  
doctors	  included	  in	  this	  study	  by	  gender.	  One	  can	  state	  that	  these	  results	  again	  demonstrate	  
differences	   in	   benzodiazepine	   prescribing	   pattern	   by	   gender.	   Females	   generally	   prescribe	  
more	   benzodiazepines,	   but	   their	   prescribing	   patterns	   have	   a	   more	   deep	   decrease	   after	  
intervention	  than	  male	  prescription	  patterns.	  	  
The	  following	  figures	  regard	  the	  mean	  DHD	  prescription	  trend	  by	  gender,	  specifically	  for	  the	  
intervened	  GPs	  in	  Amadora.	  
	  
Figure	  10:	  Graphical	  analysis	  of	  the	  mean	  DHD	  prescribing	  pattern	  of	  intervened	  GPs	  from	  Amadora	  by	  gender	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Figure	  11:	  Graphical	  comparison	  of	  DHD	  mean	  values	  trend	  for	  the	  intervened	  Amadora	  group,	  by	  gender.	  
	  
	  
	   Female	  gender	   Male	  gender	  
Mean	  DHD	   Coef.	   95%	  conf.	  
interval	  





433.015	   366.427	  –	  
499.604	  





448.889	   392.181	  –	  
505.598	  





6.264	   -­‐2.783	  –	  
15.312	  





-­‐10.784	   -­‐18.804	  –	  
2.764	  
0.011	   -­‐1.743	   -­‐5.553	  –	  
2.068	  
0.352	  
Table	  7:	  Regression	  analysis	   for	  prescriptions	  of	   intervened	  group	  from	  Amadora,	  by	  gender.	   Intercept	  before	   intervention	   is	  
the	  predicted	  mean	  at	  time	  -­‐1;	   Intercept	  after	   intervention	   is	  the	  predicted	  mean	  at	  time	  0;	  Slope	  before	   intervention	   is	  the	  
slope	  when	  the	  time	  scale	  is	  less	  than	  0;	  Slope	  after	  intervention	  is	  the	  slope	  when	  the	  time	  scale	  is	  0	  or	  higher.	  
Figures	  10	  and	  11	  show	  that	  female	  intervened	  gender	  GPs	  from	  Amadora	  were	  prescribing	  
more	   before	   intervention,	  with	   an	   increasing	   trend	   in	   the	   year	   before	   intervention	   (slope	  
before	   intervention	   =6.264	   with	   p=0.165),	   and	   they	   kept	   prescribing	   more	   than	   male	  
prescribers,	  although	  with	  a	  reduction	  in	  benzodiazepine	  prescription	  immediately	  after	  the	  
intervention	  period	   (slope	  after	   intervention	  =-­‐10.784	  with	  p=0.011).	   There	   is	   a	   significant	  
difference	   between	   slopes	   before	   and	   after	   intervention	   for	   female	   gender	   (difference	  
between	   slopes	   =-­‐17.05	  with	   p=0.008).	   Concerning	  male	   gender,	   their	   BZD	   prescription	   is	  
lower	   than	   for	   females.	   Before	   intervention,	  male	   gender	   presents	   a	   very	   small	   and	   non-­‐
significant	  decreasing	  trend	  in	  prescription	  (slope	  before	  intervention	  =-­‐0.474	  with	  p=0.821).	  
After	  intervention,	  male	  gender	  maintains	  a	  non-­‐significant	  decreasing	  trend	  in	  prescription	  
(slope	  after	   intervention	  =-­‐1.743	  with	  p=0.352).	   There	  was	  no	   significant	  difference	   in	   the	  
prescription	   trend	   for	   male	   gender	   before	   and	   after	   intervention	   (difference	   in	   slopes	   =-­‐
1.269	  with	  p=0.651).	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The	   following	   figures	   regard	   the	   mean	   DHD	   prescription	   trend	   specifically	   for	   the	   non-­‐
intervened	  GPs	  in	  Amadora	  by	  gender.	  
	  
Figure	  12:	  Graphical	  analysis	  of	  the	  mean	  DHD	  prescribing	  pattern	  of	  non-­‐intervened	  GPs	  from	  Amadora	  by	  gender	  
	   	  
	  
Figure	  13:	  Graphical	  comparison	  of	  DHD	  mean	  values	  trend	  for	  the	  non-­‐intervened	  Amadora	  group	  by	  gender.	  
	  
	   Female	  gender	   Male	  gender	  
Mean	  DHD	   Coef.	   95%	  conf.	  
interval	  





333.747	   290.737	  –	  
376.757	  





347.906	   311.277	  –	  
384.535	  





5.092	   -­‐0.752	  –	  
10.936	  





-­‐3.937	   -­‐9.117	  –	  1.243	   0.129	   -­‐5.260	   -­‐10.419	  –	  
0.102	  
0.046	  
Table	  8:	  Regression	  analysis	  for	  prescriptions	  of	  non-­‐intervened	  group	  from	  Amadora,	  by	  gender.	  Intercept	  before	  intervention	  
is	  the	  predicted	  mean	  at	  time	  -­‐1;	  Intercept	  after	  intervention	  is	  the	  predicted	  mean	  at	  time	  0;	  Slope	  before	  intervention	  is	  the	  
slope	  when	  the	  time	  scale	  is	  less	  than	  0;	  Slope	  after	  intervention	  is	  the	  slope	  when	  the	  time	  scale	  is	  0	  or	  higher.	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As	   previously,	   the	   same	   analysis	   was	   performed	   to	   describe	   the	   slopes	   of	   the	   trend	   in	  
prescription	  for	  non-­‐intervened	  GPs	  from	  Amadora.	  	  
Figures	  12	  and	  13	  demonstrate	  there	  is	  also	  a	  difference	  in	  prescribing	  patterns	  by	  gender	  in	  
the	  non-­‐intervened	  GPs	  from	  Amadora.	  	  
Female	  GPs	  were	  prescribing	  more	  before	  intervention,	  with	  an	  increasing	  trend	  in	  the	  year	  
before	   intervention	   (slope	   before	   intervention	   =5.092	   with	   p=0.084),	   and	   they	   keep	  
prescribing	   more	   than	   men,	   although	   with	   a	   non-­‐significant	   reduction	   in	   benzodiazepine	  
prescription	   after	   the	   intervention	   period	   (slope	   after	   intervention	   =-­‐3.94	   with	   p=0.129).	  
There	   is	   a	   significant	   difference	   between	   slopes	   before	   and	   after	   intervention	   for	   female	  
gender	  (difference	  between	  slopes	  =-­‐9.028	  with	  p=0.026).	  	  
Concerning	  male	  GPs,	  their	  BZD	  prescription	  is	  lower	  than	  for	  females.	  Before	  intervention,	  
non-­‐intervened	  male	  gender	  GPs	  present	  a	  non-­‐significant	  decreasing	  trend	   in	  prescription	  
(slope	  before	   intervention	   =-­‐0.436	  with	   p=0.878),	  which	   is	   very	   similar	   to	   the	  prescription	  
trend	   of	   intervened	  male	   GPs.	   After	   intervention,	  male	   gender	   GPs	   presents	   a	   significant	  
decreasing	  trend	  in	  prescription	  (slope	  after	   intervention	  =-­‐5.260	  with	  p=0.046).	  There	  was	  
non-­‐significant	   difference	   in	   the	   prescription	   trend	   for	   male	   gender	   before	   and	   after	  
intervention	  (difference	  between	  slopes	  =-­‐4.824	  with	  p=0.211).	  	  
Finally,	   the	   following	   figures	   analyse	   the	   mean	   DHD	   prescription	   trend	   for	   the	   non-­‐
intervened	  GPs	  in	  Almada,	  by	  gender.	  	  
	  
Figure	  14:	  Graphical	  analysis	  of	  the	  mean	  DHD	  prescribing	  pattern	  of	  non-­‐intervened	  GPs	  from	  Almada	  by	  gender	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Figure	  15:	  Graphical	  comparison	  of	  DHD	  mean	  values	  trend	  for	  the	  intervened	  Almada	  group	  by	  gender.	  
	  
	   Female	  gender	   Male	  gender	  
Mean	  DHD	   Coef.	   95%	  conf.	  
interval	  





302.348	   275.513	  –	  
329.182	  





286.234	   263.381	  –	  
309.087	  










-­‐3.707	   -­‐6.939	  –	  0.475	   0.027	   0.579	   -­‐2.561	  –	  
3.718	  
0.705	  
Table	  9:	  Regression	  analysis	  for	  prescriptions	  of	  non-­‐intervened	  group	  from	  Almada,	  by	  gender.	  Intercept	  before	  intervention	  is	  
the	  predicted	  mean	  at	  time	  -­‐1;	   Intercept	  after	   intervention	   is	  the	  predicted	  mean	  at	  time	  0;	  Slope	  before	   intervention	   is	  the	  
slope	  when	  the	  time	  scale	  is	  less	  than	  0;	  Slope	  after	  intervention	  is	  the	  slope	  when	  the	  time	  scale	  is	  0	  or	  higher.	  
In	  figure	  14	  some	  results	  stand	  out	  when	  comparing	  with	  the	  previous	  similar	  analysis	  to	  the	  
other	  groups	  of	  GPs	  from	  Amadora.	  Firstly,	  benzodiazepines’	  total	  prescription	  amount	  and	  
trends	  are	  lower	  in	  Almada	  than	  in	  Amadora	  (for	  intervened	  and	  for	  non-­‐intervened	  groups	  
of	  GPs).	  Secondly,	  the	  differences	  in	  the	  amount	  of	  prescription	  and	  trends	  are	  smaller	  when	  
comparing	  female	  to	  male	  prescribers.	  
As	  figure	  15	  and	  table	  9	  further	  demonstrate,	  female	  gender	  GPs	  in	  Almada	  were	  prescribing	  
more	   than	  male	   gender	  GPs	  before	   intervention,	  with	   a	   significant	   increasing	   trend	   in	   the	  
year	  before	  intervention	  (slope	  before	  intervention	  =4.867	  with	  p=0.011),	  and	  they	  kept	  an	  
higher	   prescription	   trend	   compared	   to	   male	   prescribers,	   although	   with	   a	   reduction	   in	  
benzodiazepine	  prescription	  after	   the	   intervention	  period	   (slope	  after	   intervention	  =-­‐3.707	  
with	  p=0.027).	  There	  is	  a	  difference	  between	  slopes	  before	  and	  after	  intervention	  for	  female	  
gender	  (difference	  in	  slopes	  =-­‐8.575	  with	  p=0.001).	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Concerning	   male	   gender	   GPs,	   before	   intervention	   their	   trend	   presents	   a	   non-­‐significant	  
decrease	   (slope	   before	   intervention	   =-­‐0.034	   with	   p=0.984).	   After	   intervention,	   male	   GPs	  
present	   a	   non-­‐significant	   increasing	   trend	   in	   prescription	   (slope	   after	   intervention	   =0.579	  
with	  p=0.705).	  There	  was	  no	  significant	  difference	  in	  the	  prescription	  trend	  for	  male	  gender	  
before	  and	  after	  the	  intervention	  period	  (difference	  in	  slopes	  =0.612	  with	  p=0.790).	  	  
A	   comparison	   between	   the	   slopes	   for	   the	   different	   groups	   of	   GPs	   before	   and	   after	  
intervention	   was	   also	   performed	   by	   gender.	   This	   analysis	   demonstrated	   there	   were	   no	  
significant	  differences	  between	  slopes	  by	  gender.	  Since	  in	  the	  general	  analysis	  it	  was	  found	  a	  
significant	  difference	  between	  the	  slopes	  after	  intervention	  of	  the	  prescription	  trend	  for	  the	  
intervened	  GP	  group	   in	  Amadora	   and	   the	  non-­‐intervened	  group	   in	  Almada	   (p<0.001),	   one	  
can	  state	  that	  this	  difference	  results	  from	  the	  combination	  of	  effects	  from	  female	  and	  male	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4.	  Discussion	  	  
4.1.	  Global	  decrease	  in	  benzodiazepine	  prescription	  
The	   initial	   general	   analysis	   demonstrated	   a	   decrease	   in	   benzodiazepine	   prescription	   trend	  
after	   the	   intervention	   period,	   which	   corresponded	   from	   May	   2010	   to	   March	   2011.	   This	  
decreasing	  trend	  happened	  in	  all	  three	  groups	  of	  GPs	  included	  in	  this	  study,	  although	  with	  a	  
larger	   differences	   in	   slopes	   pre	   and	   post-­‐intervention	   and	  more	   statistical	   significance	   for	  
the	  intervened	  group	  from	  Amadora.	  
The	   author	   searched	   the	   Portuguese	   General	   Health	   Administration	   (Direcção	   Geral	   de	  
Saúde	   –	   DGS)	   database	   for	   any	   guidelines	   or	   information	   advises	   in	   order	   to	   justify	   the	  
general	  decrease	  in	  benzodiazepine	  prescription.	  	  
In	  November	  2011	  a	  non-­‐compulsory	  guideline	  was	  published	  concerning	  the	  treatment	  of	  
anxiety	  and	   insomnia	  (Pestana	  and	  Teixeira	  2011).	   In	  this	  guideline	   it	  was	  advised	  to	  avoid	  
long-­‐term	  benzodiazepine	  utilisation,	  so	  one	  could	  state	  that	  its	  publication	  would	  probably	  
lead	   to	   a	   reduction	   in	   prescription.	   However,	   the	   data	   showed	   a	   decrease	   right	   after	   the	  
intervention	  period	  (from	  May	  2010	  to	  March	  2011),	  which	  might	  indicate	  that	  the	  change	  in	  
prescription	   pattern	   is	   due	   to	   the	   intervention.	   Nevertheless,	   the	   guideline	   was	   probably	  
subject	   to	   public	   discussion	   –	   meaning,	   discussion	   between	   peers	   –	   before	   it’s	   definitive	  
publication.	  	  
A	  search	  on	  both	  the	  National	  Authority	  of	  Medicines	  and	  Health	  Products	  (INFARMED)3	  and	  
on	   the	   European	   Medicines	   Agency	   (EMA) 4 	  was	   performed	   in	   order	   to	   verify	   if	   any	  
information	  or	  warning	  was	  published	  concerning	  each	  of	  the	  active	  substances	  included	  in	  
the	   analysis.	   As	   previously,	   no	   appropriate	   information	   was	   found	   in	   order	   to	   justify	   the	  
global	  decrease	  in	  benzodiazepines	  in	  the	  period	  right	  after	  the	  intervention.	  	  
The	   author	  was	   aware	   that	   the	  USFs	   primary	  health	   care	   centres	   sign	   annually	   a	   contract	  
with	  the	  governmental	  financing	  agency	  in	  which	  some	  quality	  goals	  are	  set5.	  A	  review	  was	  
performed	  in	  order	  to	  verify	  if	  there	  was	  any	  article	  in	  these	  contracts	  concerning	  specifically	  
the	  prescription	  of	  benzodiazepines.	  Contracts	   for	  Amadora	  and	  Almada	   in	  2010	  and	  2011	  
had	  an	  explicit	   recommendation	   concerning	  both	  benzodiazepines	   and	  antidepressants.	   In	  
this	   recommendation	   the	   combined	   increase	   of	   these	   two	   groups	   of	   medicines	   was	  
proposed.	   In	  Amadora	   (the	  region	  where	  GPs	  were	   intervened),	  an	   increase	  was	  proposed	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
3	  http://www.infarmed.pt/portal/page/portal/INFARMED	  
4	  http://www.ema.europa.eu/ema/	  
5	  Contratos	  programa	  para	  os	  agrupamentos	  de	  Centros	  de	  Saúde:	  Agrupamento	  de	  Centros	  de	  Saúde	  VI:	  Amadora	  e	  de	  
Almada-­‐Seixal	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from	   93	   DHD	   to	   100	   DHD	   and	   in	   Almada	   an	   increase	   from	   112	   DHD	   to	   130	   DHD.	   In	   this	  
sense,	  it	  also	  cannot	  be	  assigned	  to	  these	  contracts	  the	  change	  in	  prescription	  pattern	  after	  
the	  intervention	  period.	  	  
Further	   research	  was	   performed	   in	   order	   to	   include	  more	   recent	   data	   contained	   in	   these	  
contracts	  but	   the	  2012	  contracts	   for	  Amadora	  and	  Almada	  were	  not	  available	  and	   in	  2013	  
the	   contracts	   stop	   referring	   to	   the	   adequate	   prescription	   of	   benzodiazepines	   (and	  
antidepressants).	  	  
Finally,	   the	   awareness	   on	   the	   negative	   effects	   of	   benzodiazepine	   long-­‐term	   utilisation	   is	  
relatively	   recent	   in	   the	   literature.	   A	   Medline	   literature	   search	   using	   the	   terms	  
“benzodiazepines”	   and	   “side-­‐effects”	   was	   performed	   to	   verify	   how	   many	   papers	   were	  
published	   in	   the	   total	   period	   of	   time	   in	   which	   the	   study	   took	   place	   (May	   2009	   to	  March	  
2012)	  and	  then	  in	  the	  3	  months	  before	  and	  after	  the	  intervention	  period	  (February	  2010	  to	  
June	  2011).	  In	  the	  first	  mentioned	  period,	  1180	  papers	  were	  published	  referring	  this	  subject	  
while	   in	  the	  second	  mentioned	  period,	  996	  papers	  were	  published.	  This	  demonstrates	  that	  
by	   the	   time	   the	   intervention	   was	   taking	   place,	   the	   scientific/medical	   community	   was	  
concerned	  about	   the	  negative	  effects	  of	  benzodiazepine’s	  utilisation.	  This	   large	  number	  of	  
papers	  might	  have	  influenced	  the	  GPs	  prescription	  pattern,	  although	  the	  author	  admits	  that	  
this	  fact	  shouldn´t	  have	  had	  such	  an	  important	  and	  general	  impact.	  	  
An	  Hawthorne	  effect	  or	  a	  contamination	  effect	  between	  groups	  of	  GPs	  was	  also	  considered	  
in	  order	  to	  explain	  the	  general	  change	  in	  prescription	  trend	  after	  the	  intervention	  period.	  	  
The	  Hawthorne	  effect	  suggests	  that	  study	  subject’s	  behaviour	  or	  study	  results	  are	  altered	  by	  
the	  subjects’	  awareness	  that	  they	  are	  being	  studied	  (Fernald	  et	  al.	  2012).	  This	  is	  specially	  a	  
concern	   when	   subjects	   are	   not	   blinded	   to	   randomization	   (Fernald	   et	   al.	   2012),	   as	   it	  
happened	   in	   this	   research	   since	   some	   GPs	   from	   each	   primary	   health	   care	   centre	   were	  
trained	  while	  others	  weren’t.	  In	  addition,	  as	  public	  relations	  activities	  and	  media	  campaigns	  
were	   held	   in	   Amadora	   at	   a	   community	   level,	   although	   not	   knowing	   the	   exact	   study	  
outcomes,	   the	   non-­‐intervened	   doctors	   from	   Amadora	   might	   have	   been	   aware	   that	   the	  
measures	   implemented	   by	   the	   OSPI-­‐Europe	   project	   would	   be	   later	   assessed,	   and	   for	   this	  
reason,	  they	  might	  have	  changed	  their	  prescription	  pattern	  due	  to	  the	  knowledge	  they	  were	  
being	  “observed”.	  The	  Hawthorne	  effect	  was	  already	  described	   in	  a	  multi-­‐practice	  audit	  of	  
benzodiazepine	   cessation	   (Holden	   2001),	   so	   one	   might	   infer	   about	   the	   influence	   of	   this	  
effect	   in	  the	  decreasing	  trend	  in	  BZD	  prescription	  after	  the	  intervention	  period	  for	  the	  two	  
groups	  of	  GPs	  prescribing	  in	  Amadora.	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Contamination	   in	   trials	   occurs	   when	   people	   who	   were	   not	   intended	   to	   receive	   an	  
intervention,	   inadvertently	   do	   so	   (Keogh-­‐Brown	   et	   al.	   2007).	   Trials	   of	   educational	  
interventions	  are	  especially	  prone	   to	   contamination	  because	   the	  active	   ingredients	   can	  be	  
transportable	   and	   difficult	   to	   confine	   (Keogh-­‐Brown	   et	   al.	   2007).	   Contamination	   tends	   to	  
reduce	   the	  magnitude	   of	   effect	   estimates	   and	   therefore	   also	   to	   increase	   the	   chance	   that	  
estimates	   will	   not	   be	   statistically	   significant,	   therefore	   causing	   bias	   and	   reducing	   power	  
(Keogh-­‐Brown	  et	  al.	  2007,	  Torgerson	  2001).	  A	  2007	  consensus	  on	  contamination	   in	  clinical	  
trials	   argued	   that	   contamination	   was	   more	   likely	   in	   trials	   conducted	   in	   settings	   where	  
subjects	   worked,	   lived	   or	   interacted	   closely	   together	   and	   where	   interventions	   were	  
desirable,	   simple	  or	  easily	   transferable	  or	  were	  aimed	  at	   increasing	  knowledge.	   It	  was	   less	  
likely	   when	   subjects	   were	   socially	   or	   physically	   separate,	   and	   where	   interventions	   were	  
complex	   or	   aimed	   at	   changing	   behaviours.	   It	  was	  more	   likely	  with	   interventions	   aimed	   at	  
health	   professionals	   than	   with	   interventions	   aimed	   at	   patients.	   It	   was	   more	   likely	   with	  
interventions	  based	  on	  broadcast	  media,	  audiovisuals	  or	  written	  information	  and	  was	  least	  
likely	  with	  computer-­‐based	  reminders	  (Howe	  et	  al.	  2007).	  	  
In	  this	  sense,	  one	  can	  discuss	  that	  the	  decrease	  in	  prescription	  trend	  after	  the	  intervention	  
period	  in	  the	  non-­‐intervened	  group	  of	  GPs	  from	  Amadora	  could	  be	  due	  to	  a	  contamination	  
effect.	   Concerning	   Almada,	   although	   the	   group	   of	   GPs	   from	   this	   region	   was	   physically	  
separated	  from	  the	  intervened	  group	  in	  Amadora,	  both	  Amadora	  and	  Almada	  primary	  health	  
care	  centres	  belong	  to	  the	  same	  Regional	  Health	  Administration	  (ARS	  LVT),	  therefore	  some	  
information	  spilling	  would	  be	  possible	  and	  a	  reasonable	  justification	  to	  the	  slight	  decrease	  in	  
BZDs	  prescription	  in	  Almada	  after	  the	  intervention	  period.	  	  
Another	  aspect	  that	  cannot	  be	  taken	  lightly	  is	  the	  effect	  of	  general	  national	  trends.	  In	  fact,	  
we	  previously	  ascertained	  a	  reduction	  of	  BZD	  utilization	  and	  prescription	  from	  2010	  both	  at	  
national	   level	   and	  at	  ARS	  LVT	   level	   (Furtado	  2013).	   This	   systemic	  effect	   could	  help	  explain	  
the	  downward	  trends	  in	  the	  three	  sites,	  pre	  and	  post-­‐intervention,	  the	  differential	  effect	  in	  
Amadora	  intervened	  GPs	  being	  due	  to	  the	  intervention	  itself.	  
A	  comparison	  between	  the	  slopes	  for	  the	  prescription	  trends	  demonstrates	  that	  the	  results	  
are	  consistent	  with	  the	  author’s	  expectations.	  There	  is	  a	  significant	  difference	  between	  the	  
slopes	  after	   intervention	  period	   for	   intervened	  GPs	   from	  Amadora	  and	   for	  non-­‐intervened	  
GPs	  from	  Almada.	  
Finally,	  since	  participants	  self-­‐selected	  themselves	  to	  integrate	  the	  intervened	  group	  of	  GPs	  
in	  Amadora,	  there	  might	  be	  a	  bias	  a	  selection	  bias	  influencing	  the	  results.	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4.2.	  Gender	  effect	  and	  needs	  
A	   detailed	   analysis	   considering	   the	   benzodiazepine	   prescription	   trend	   of	   the	   three	   GPs	  
groups	   demonstrated	   the	   existence	   of	   a	   difference	   in	   the	   prescribing	   pattern	   between	  
female	  and	  male	  prescribers.	  	  
In	  all	  groups	  (even	  for	  Almada	  where	  the	  difference	  between	  genders	  was	  smaller),	  female	  
GPs	  prescribed	  a	  greater	  amount	  of	  benzodiazepines.	  	  
The	  available	  dataset	  does	  not	   allow	   to	   further	  exploring	   the	   reasons	   and	   the	  meaning	  of	  
this	  difference.	  	  
It	  would	  be	  expected	  to	  have	  patients	  with	  similar	  characteristics	  regardless	  the	  prescriber’s	  
gender,	  so	  one	  might	  infer	  that	  these	  differences	  are	  due	  to	  characteristics	  of	  the	  prescriber.	  
The	   author	   performed	   a	   literature	   review	   searching	   for	   studies	  with	   similar	   female	   higher	  
BZDs	   prescription	   trends	   and	   also	   for	   reasons	   for	   this	   fact.	   There	   is	   a	   lack	   in	   literature	  
concerning	   these	  questions,	   since	  most	  of	   the	  papers	   found	   focussed	   the	  patient’s	  gender	  
(most	  BZDs	  were	  reported	  to	  be	  prescribed	  to	  women)	  instead	  of	  the	  prescriber’s.	  	  
Three	   references	   were	   found	   concerning	   differences	   in	   attitudes	   towards	   depression	  
identification	  and	  treatment	  by	  primary	  health	  care	  doctors,	   in	  which	   it	  was	  demonstrated	  
that	   female	   prescribers	   were	   more	   insecure	   and	  might	   hesitate	   in	   establishing	   a	   definite	  
diagnose	  when	  comparing	  to	  male	  doctors.	  These	  reasons	  might	  justify	  a	  delay	  in	  prescribing	  
antidepressants,	   hence	   choosing	   to	   prescribe	  more	   frequently	   BZDs	   (Rollman	   et	   al.	   2001,	  
Andersson,	  Lindberg,	  and	  Troein	  2002,	  Gusmão	  2005).	  
A	   comparison	   of	   the	   slopes	   for	   the	   prescription	   trends	   by	   gender	   suggests	   that	   the	  
decreasing	  BZD	  prescription	  pattern	  after	  intervention	  in	  Amadora	  is	  due	  to	  the	  changing	  in	  
female	  doctors	  prescription	  pattern.	  This	  indicates	  that	  the	  effectiveness	  of	  the	  intervention	  
in	  Amadora	  was	  mostly	  due	  to	  the	  decrease	  in	  BZD	  prescription	  from	  female	  GPs.	  One	  might	  
infer	   that	   since	   females	  were	   prescribing	  more	   before	   intervention,	   it	   would	   be	   easier	   to	  
integrate	  the	  new	  knowledge	  derived	  from	  the	  intervention	  into	  clinical	  practice.	  	  
4.3.	  The	  need	  for	  training	  sustainability	  
Finally,	   the	  author	  considered	   that	   the	   increasing	   trend	   in	  prescription	   that	   is	   shown	   in	  all	  
graphical	  analysis	  9	  to	  10	  months	  after	  the	  intervention	  period	  (corresponding	  to	  the	  period	  
from	  February	  2011	  to	  December	  2011)	  is	  worthy	  of	  comments.	  	  
In	   order	   to	   find	   a	   reason	   for	   this	   change	   in	   pattern	   occurring	   in	   all	   three	   groups	   of	   GPs	  
included	   in	   this	   study,	   the	   same	   previous	   review	   of	   (1)	   the	   Portuguese	   General	   Health	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Administration	   documents	   database,	   (2)	   the	   National	   Authority	   of	   Medicines	   and	   Health	  
Products	   (INFARMED)	   and	   of	   (3)	   the	   European	   Medicines	   Agency	   (EMA)	   was	   performed	  
without	  any	  significant	  finding.	  	  
The	  mentioned	  contracts	  signed	  by	  Amadora	  and	  Almada	  in	  2010	  and	  2011	  mentioning	  as	  a	  
goal	   the	   increasing	   prescription	   of	   benzodiazepines	   and	   antidepressants	   also	   shouldn´t	  
explain	  that	  fact.	  	  
Two	   more	   possible	   explanations	   for	   this	   increase	   in	   BZD	   prescription	   trend	   should	   be	  
considered.	  	  
The	   first	   is	   the	   possible	   loss	   of	   intervention	   effect	   for	   both	   groups	   of	   GPs	   prescribing	   in	  
Amadora.	   Several	   publications	   point	   to	   this	   phenomenon	   happening	   a	   few	   months	   after	  
educational	  interventions	  and	  point	  to	  the	  need	  for	  continuous	  intervention	  and	  monitoring	  
in	  order	  to	  assure	  the	  maintenance	  of	  the	  effect	  (Smith	  and	  Tett	  2010,	  Smith	  et	  al.	  2006).	  	  
The	  second	   is	   the	   influence	  of	   the	  2008	  economic	  crisis	  on	  mental	  health.	  Allegedly,	   there	  
was	   a	   direct	   negative	   effect	   of	   economic	   crisis	   on	   mental	   health,	   mental	   disorders	   and	  
mental	  health	  symptoms	  (Kentikelenis	  et	  al.	  2011,	  Khang,	  Lynch,	  and	  Kaplan	  2005,	  Stuckler	  
et	   al.	   2009).	   The	   situation	   of	   unemployment	   and	   debt	   might	   have	   significantly	   increase	  
complaints	  of	  anxiety	  in	  the	  Portuguese	  population	  (Escoval	  et	  al.	  2012)	  leading	  to	  a	  greater	  
demand	  for	  benzodiazepines.	  	  
On	   the	   other	   hand,	   the	   crisis	   did	   not	   impact	   suicide	   rates	   (Ayuso-­‐Mateos,	   Barros,	   and	  
Gusmão	  2013).	  It	  is	  possible	  that	  in	  the	  short-­‐term,	  BZD	  increase	  after	  2011	  helped	  to	  stop	  
severe	  effects	  of	   increased	  prevalence	  of	  mental	   pathology	   thus	   restraining	  more	   suicides	  
from	  happening.	  In	  the	  future,	  negative	  effects	  of	  that	  increase	  should	  be	  seen.	  
4.4.	  Limitations	  
	  
Almada	  region	  seemed	  to	  be	  a	  good	  choice	   for	  control	   region	  for	   this	  study	  because	  of	   its	  
similarities	   in	   terms	   of	   socio-­‐demographic	   structure	   and	   also	   because	   the	   Tagus	   river	  
separating	   the	   two	   regions	  would	   prevent	   the	   existence	   of	   contamination	   between	   them.	  
However,	   the	   analysis	   performed	   demonstrated	   that	   doctors	   prescribing	   in	   Almada	   had	   a	  
benzodiazepine	   prescription	   trend	  with	   significant	   differences	   concerning	   the	   amount	   and	  
the	  distribution	  by	  prescriber’s	  gender	  comparing	  to	  doctors	  prescribing	  in	  Amadora.	  	  
The	  study	  would	  have	  had	  higher	  validity	  if	  randomisation	  at	  the	  level	  of	  primary	  health	  care	  
centres	   had	   been	   performed.	   In	   fact,	   since	   the	   GPs	   organised	   among	   themselves	   to	  
participate	   and	   comply	  with	   the	   quotas	   (50%	   of	   the	   fully	   active	   GPs	  working	   in	   Amadora	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were	  required	  to	  participate),	  a	  selection	  bias	  might	  have	  occurred.	  This	  self-­‐selection	  might	  
have	  led	  to	  the	  inclusion	  in	  this	  study	  of	  doctors	  with	  similar	  prescribing	  patterns	  or	  learning	  
needs	  (Would	  intervened	  doctor	  be	  the	  ones	  with	  a	   larger	  number	  of	  anxious	  patients?	  Or	  
the	  ones	  more	  aware	  of	  their	  inadequate	  prescribing	  patterns?	  Or	  the	  ones	  more	  interested	  
in	   learning?)	   If	   randomisation	  would	  not	  again	  be	  possible,	  matching	  should	  be	  performed	  
taking	   into	   account	   not	   only	   the	   type	   of	   primary	   health	   care	   centre	   (USFs	   vs.	   UCSP),	   as	  
performed	   in	   this	   study,	   but	   also	   the	   baseline	   prescription	   trend,	   the	   GPs’	   gender	   and	  
possibly	  the	  doctors’	  clinical	  experience.	  
The	   mean	   DHD	   values	   obtained	   were	   substantially	   higher	   than	   the	   values	   for	   DHD	  
prescription	  known	  to	  Portugal:	  215	  DHD	  in	  our	  study	  versus	  96	  DHD	  for	  the	  year	  of	  2012)	  
(Furtado	  2013).	  This	  was	  due	  to	  the	  fact	  that	  for	  computing	  DHD	  values	  the	  total	  number	  of	  
patients	   observed	   by	   each	   doctor	   was	   chosen	   instead	   of	   the	   number	   of	   inhabitants	   of	  
Amadora	  and	  Almada.	  This	  choice	  was	  made	  after	  a	  preliminary	  analysis	   that	  showed	  very	  
low	   DHD	   when	   the	   number	   of	   inhabitants	   was	   used,	   demonstrating	   that	   a	   significant	  
number	  of	  inhabitants	  still	  didn’t	  use	  the	  primary	  health	  care	  services	  in	  2009-­‐2011.	  	  
In	  some	  cases	  the	  data	  provided	  for	  the	  number	  of	  patients	  observed,	  and	  used	  to	  compute	  
the	  DHD	  values,	  was	  missing	  or	  the	  number	  provided	  was	  substantially	  low	  compared	  to	  the	  
number	  of	  prescriptions	  included	  in	  the	  original	  prescription	  database.	  In	  those	  cases,	  it	  was	  
chosen	  to	  replace	  the	  number	  of	  patients	  observed	  by	  the	  number	  of	  patients	  to	  whom	  any	  
prescription	  had	  been	  included	  in	  the	  original	  database.	  
	   41	  
5.	  Conclusions	  
This	   study	   demonstrates	   how	   a	   single	   intervention	   might	   have	   a	   positive	   impact	   on	  
improving	  prescription	  trends.	  	  
Since	   a	   single	   intervention	   to	   GPs	   was	   performed	   resulting	   in	   a	   significant	   change	   in	  
benzodiazepine	  prescription	  pattern,	  surely	  a	  cost-­‐effectiveness	  analysis	  to	  the	  results	  would	  
demonstrate	  the	  benefits	  of	  this	  intervention	  and	  the	  relevance	  for	  its	  replication.	  	  
Considering	   the	   worrying	   benzodiazepine	   consumption	   in	   Portugal,	   the	   replication	   of	   this	  
educational	   intervention	   in	   other	   primary	   health	   care	   setting	   would	   possibly	   be	   a	   good	  
suggestion	  to	  the	  Mental	  Health	  authorities	  to	  implement	  in	  the	  future.	  	  
It	   was	   demonstrated	   that	   prescription	   trend	   of	   benzodiazepines	   is	   different	   for	  male	   and	  
female	   prescribers.	   The	   reasons	   for	   this	   fact	   could	   be	   further	   explored	   and	   considered	   in	  
future	  studies	  concerning	  interventions	  to	  improve	  prescription	  patterns.	  	  
Finally,	   considering	   that	   10	   months	   after	   intervention	   there	   was	   a	   slight	   increase	   in	  
benzodiazepine	  prescription,	   these	  data	  point	   to	   the	  need	  of	   re-­‐trainings,	   in	  which	  case	  e-­‐
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